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INIHGDUCIICM i
*•Atebrin and Malaria* - • Atebrin was. prepared 
in Germany in lb32 and was found to have marked 
anti-malarial properties."^ In 1937 it was 
generally agreed that the drug was effective 
in the treatment of falciparum, tertian, and 
quartan maiarias ana its superiority over quinine '
as a preventive of malaria had also been clearly
3 4 5 6 7established, 9 9 9 9 though it did not supplant
quinine because of sporadic reports of serious
7effects following its use as a prophylactic and
3therapeutic • agent. More data on the toxicity of 
atebrin were required before, it could be recommend- 
• ed on a large scale for malaria prevention. However, 
a decision was forced by Japan’s entry into the war 
at the end of 1941. -This event resulted in the loss 
of natural sources of quinine and made it certain
*Atebrin or atebrin-like compounds have different 
names in almost every country in which they.are 
produced. Synonyms are:- Atebrin - German,
Crinodora - Italian, duinacrine - I'rench, Acriquine - 
Jlussian, 3uinecrine ^previously Atabrine) — American, 
Mepacrine - British.
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that armies would have to be maintained in highly 
malarious parts of the world. Since atebrin 
could be prepared synthetically and -quinine could 
not, the risk oi toxic effects from atebrin had to 
be weighed against its advantages as a. malarial 
preventive. Experience in the 1914-13 world war
was decisive: the risk of atebrin toxicity was
9worth taking. Investigations on the synthesis 
of atebrin were made and methods for large scale 
production were developed. A drug, named mephcrine, 
was prepared that was claimed to be the same as 
German atebrin.
'i’he investigations to be dealt with in this
thesis started in 1943. i'heir object was to assess,
under controlled conditions, the value of mepacrine*
as-a preventive of falciparum malaria and bo deter­
mine the best methods of employing the drug for 
this purpose. lalciparum malaria was chosen for 
experimental infection because this was the type 
of malaria most likely to cause a military disaster. 
Hie work has entailed the following:- employment
* Synonyms' are malignant tertian, and tertian 
malaria.
of healthy volunteers who were willing to be 
infected with malaria; provision of large 
numbers of anopheline mosquitoes carrying spor- 
osoites; hospital beds for observation and 
treatment; and laboratory facilities for micro­
scopic and biochemical examinations.
In previous work of this kind, dose of 
drug has been employed as the reference index. 
Earlier workers have sought to define, more or 
less by trial and error, the. dose that would give 
a desired therapeutic effect without- causing toxic 
reactions. The greater the difference between 
minimal therapeutic dose and minimal toxic dose - 
the greater, the therapeutic latitude in the employ­
ment of the drug. • But an inevitable serious 
drawback to this approach is.the variation in 
clinical response of different individuals to the 
same dose of drug. Large numbers of observations 
usually had to be made and years had to elapse • 
before the therapeutic limits of a new drug could 
be properly defined. fhis method of investigation
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was not suitable for the needs of the Army in
1943 because time was of great importance. The
great advantage of the new approach to sulphon-
amide chemotherapy over the older empiirical
■ ' "  10 method outlined above, was pointed out by Shannon
and was largely responsible for the method of
11
investigation employed in this work. James 
considered that the-morphological changes in 
malaria parasites observed soon after administ­
ration of mepacrine -was evidence of a direct 
action of the drug on parasites. Shannon 
concluded that if mepacrine acted directly on 
parasites, then this action probably depended 
on the concentration of the. drug in the body.
This conception offered'a new approach to the 
study of anti-malarial drugs and the introduction
of accurate methods for estimating minute amounts
12 13of mepacrine in body fluids 9 provided a 
unique opportunity to investigate the chemother- 
peutic action of mepacrine in relation to its 
concentration in body fluids and tissues. The
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methods introduced were sufficiently'sensitive 
to allow ranges of concentration to be estimated
that were much lov/er.than had ever been attempted 
before in chemotherapeutic investigations.'
Under the new scheme the value of mepacrine 
for malaria prevention has been assessed in the 
first place by giving varying doses of the drug 
to volunteers who had never previously been exposed 
to malaria, and then comparing their reactions to 
experimental malarial infection with the reactions 
of non-immune controls who were similarly infected 
but received no drug. The chemotherapeutic action 
of mepacrine in relation to the concentration of 
the drug, in the blood has been examined by comparing
(l) - the blood mepacrine levels of volunteers v/ho 
took mepacrine but developed malaria with (U) — the 
levels of similar volunteers who escaped the disease 
If the blood mepacrine should prove to be an index 
of the chemotherapeutic action o.f the drug, then it 
was hoped to define the ;minimum concentration that 
would prevent malaria;- and, by concurrent
6 -
sinvestigation of the pharmacology and toxicity 
of mepacrine, to define the best methods of 
maintaining an effective blood.level.
fhe investigations are described in five 
.parts. Part 1 deals with the chemotherapeutic, 
action of mepacrine in falciparum malaria; part 2, 
with the pharmacology of the drug; part 3, with 
its toxicity; part 4, with the application of the 
results in the prevention and treatment of malaria 
with mepacrine; and part 5, with detailed results 
in the form of tables, graphs, and illustrations. 
For ease of reference the.work is presented'in two 
volumes. The first volume includes parts 1, 2, 3, 
and 4; the second volume, part 5.
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PART 1
THE GHEMOTHERARjSDTIC AGHOIT OR
ivEGPiiCRIRjS IN  RAjjCIPARUM MALARIA*
Rifty-five healthy volunteers taking different 
doses of mepacrine were experimentally infected with 
sporozoites of falciparum malaria to investigate the 
following
1. - The reactions of volunteers taking mepacrine 
to experimental malarial infection.
2. - The relation between dose of mepacrine 
and the value of the drug as a malarial preventive.
3. - The relation between blood mepacrine and 
the chemotherapeutic action of the drug in the prevent­
ion of falciparum malaria.
This part of the investigation was carried out in 
collaboration with K.Mellanby, D.Sc., VVfD.Nicol, R.R.C.j?.,
and P.G.Ghute, R.R.E.G.
The majority of .the volunteers were members of the 
Rriends’ Ambulance Unit and Pacifists’ Service ■ Unit and 
were recruited and organised by Dr.Mellanby. P.Gr.Shute 
prepared batches of infected mosquitoes, infected the 
volunteers,. and examined all blood films for parasites^ 
at the Ministry of Health Laboratory, Horton. -Dr.vf*D.Wicol 
.made clinical observations and was responsible for tne 
treatment of the first three groups of volunteers who 
were infected. The writer was responsible for blood- 
mepacrine,estimations throughout, and for clinical 
‘Observations and treatment of the fourth and fifth 
groups of vo1unteers.
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Methods of Infection. — Seven Volunteers were 
infected with an Italian strain of falciparum 
malaria, ana 48 with a Roumanian strain.' Fifty- 
volunteers were infected by exposure, on 1 to 4 
occasions, to the bites of mosquitoes v/hose salivary 
glands- contained numerous sporozoites. The other 
five volunteers were infected by intravenous inject­
ion of a sporozoite-gland .suspension prepared by
\
dissecting the salivary glands of infected•mosquitoes, 
and after'rupture, suspending them in Locke’s solution. 
Immediately after biting, the number of mosquitoes 
that had fed . on a volunteer was counted by observing 
the r>resence -or absence of fresh blood in the mos­
quitoes;. large numbers of sporozoites were demonstrated 
in the salivary glands of the majority of mosquitoes 
that had actually fed. Similarly, only glands that 
contained numerous sporozoites v/ere used, to prepare 
the sporozoite-gland sust)@nsiob for intravenous 
injection..
To ensure that the mosquito bites and the 
sporozoite-gland suspensions'were able to induce
\
malaria, an untreated control volunteer who had 
never been exposed to malaria was. infeqted along 
with each group of volunteers taking mepacrine.
Without exception the controls developed' malaria 
7 to 14 days after sporozoite infection; so that 
it was reasonable to attribute absence of malaria 
in the volunteers taking mepacrine to the action 
o f the drug.
Reactions to Sporozoite Infection "
* Thirteen of the 55 volunteers developed malaria. 
Twenty'others had fever ranging from 100 to 103°F., 
but parasites were not found in their blood despite^ 
careful .search of thick and thin films. „ The malarias 
and the fevers apneared 9 to 21 days after the first 
or last sporozoite infection. fever with parasitaemia 
was of one day’s duration in 15 volunteers and was 
characterised by a rapid rise of temperature and an 
equally rapid fall. In the other 6 volunteers the
fever was remittent or intermittent, and 2 or 3 
-temperature peaks were recorded over a period of 2 
to 6 days. Representative temperature charts of * <
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fevers and malarias are shown in Graph 1 (Vol.2 p3b). 
The symptoms that accompanied the fever without 
demonstrable parasitaemia varied in severity from 
minor effects that did not require bed treatment 
to incapacitating reactions that were indistinguish­
able clinically from an acute attack of malaria.
The minor effects were mainly malaise .and headache, 
often diagnosed by the men themselves as the "start 
of a cold in the head", but a nasal discharge,- the 
usual sign of acute coryza, did not appear. The 
severe reactions were .characterised b y .sensations 
of cold followed by feelings of-warmth accompanied 
by occipital headache, pain behind the eyes, and 
pains in the neck, back, and limbs. All grades 
of severity between minor and severe reactions we re 
encountered.
The incidence of malaria, and of fever 
without parasitaemia, in five groups of volunteers 
over a period of a year is shown in Table 1 (Vol.2 pi) 
Fever without parasitaemia appeared in all groups 
although they were infected with .sporozoites at
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different times of the year. Its 'incidence was 
no higher in December 1943 when influenza was 
prevalent than in June 1944 when the risk of 
contracting intercurrent infection was minimal.
When, first encountered, fever without 
demonstrable parasitaemia was regarded as an 
incidental event, probably due to an intercurrent 
infection, because complete reliance was placed 
.on prolonged examination;of blood films to disclose 
parasites in all patients with malaria. But this 
'view had to be revised when fever kept reappearing 
in volunteers taking, mepacrine and other antimalarial 
drugs after experimental infection with sporozoites 
of falciparum malaria. Fever is now considered to 
be a sequel to malarial infection. This view has 
been strengthened- by the successful transmission 
of malaria to another individual by injecting the 
blood of a volunteer when fever without obvious 
parasitaemia developed.
Dose of Mepacrine and Falciparum MalariA.
The volunteers who remained at work, took
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mepacrine in the presence of a non-medical witness 
and a signature in a diary was obtained for each 
dose taken. There was no reason to believe"that 
the drug v/as not taken as prescribed. Two mepacrine- 
dosage regimes were employed:-
a )  a daily dose of O'.lg. mepacrine 
(2) a loading dose of l.Og. in three con­
secutive days, (O.lg. on day 1, 0.3g. on day 2, and 
0.6g. on day 3) followed by O.lg. daily for variable 
periods up to 25 days (see Table 2 Vol.2 p2).
A loading dose of l.Og. in 3 days, followed 
by O.lg. on the day of infection and for 24 days 
thereafter, was found to be most effective in prevent­
ing malaria. . Hone of the volunteers treated in this 
way developed a frank attack of the disease. When 
a daily dose of O.lg. was given for 21 and 35 days 
before infection, and for 28 and 24 days after infect­
ion, 1 in 25 infected volunteers developed malaria.
On the other hand when dosing with O.lg. daily for 
20 days started on the day of infection, 2 -of 6 infected 
volunteers develop)ed malaria. Similarly, when a
loading dose of l.Og. was given for 3 days before 
infection, followed- by O.lg. on the day of infect­
ion, and for the next three days, all 5 volunteers 
developed malaria.
Fever without demonstrable parasitaemia 
occurred in volunteers taking each regime so that 
no relation could be established between dose of 
mepacrine and this condition.
f
These findings suggest that, in general, 
dose of mepacrine is directly' related to prevention 
'of frank malaria but that assessment of results on a 
dosage basis has serious limitations. In the first 
place‘the number of volunteers is too fev; to make 
sound conclusions; secondly, no explanation .can be 
given-why some individuals develop malaria while 
others taking the same doses of mepacrine escape the 
disease; and thirdly, fever without demonstrable 
narasitaemia appears to bear no relation to dose.
For these reasons, blood mepacrines were employed 
in the hope that they would provide a better index 
to assess more precise^ the chemotherapeutic action
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of mepacrine.
Blood Mepacrine and Falciparum Jfelaria 
The relation of blood mepacrine to the 
chemotherapeutic action of the drug in falciparum • 
malaria has been examined by giving volunteers 
different doses of mepacrine, infecting them with 
sporozoites of .falciparum malaria, and then .compar­
ing the blood mepacrines of the volunteers who 
developed malaria,, with the blood mepacrines of 
those who escaioed the disease. First, the method 
of estimating blood mepacrine will be outlined; 
second, the findings will be recorded separately 
for the occurrence, .of malaria and fever without 
parasitaemia.
Bl.ood-mepacrine Estimation. - When the invest­
igations started, three methods of estimating
mepacrine in tissues and body fluids had been
13developed: the Masen method, and the single-
and double-extraction methods of Brodie and Uden- 
12friend. These methods required extraction agents
of a high standard of purity.- Suitable extraction
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agents.for Masen’s method and for the single 
extraction method of Brodie and Udenfriend were 
obtainable. In both' these methods small blank 
values were obtained. The single extraction
method of Brodie and Udenfriend was selected 
because it required only one ..extracting agent and 
because it had been shown to combine high specificity 
with excellent extraction recoveries over the range 
of concentration likely to be encountered when small 
doses of mepacrine are given. Estimations had to 
be made 011 whole blood- as 'the only instrument avail­
able for measuring low fluorescent intensities was 
a Hilger Bluorimeter. After modification it was
capable of reading a concentration of mepacrine- 
equivalent to about 20 ug. per litre of blood. It 
was therefore suitable for whole blood but not for 
plasma estimations, in men taking the small doses 
of the drug employed in the prevention of malaria.
The following is a brief account of the method.
Blood is laked with distilled water. An alkali 
buffer and ethylene dichloride are added and the
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mixture is shaken. The mepacrine plus the 
degradation products are selectively extracted into 
the ethylene dichloride. The ethylene dichloride 
is th,en separated and washed in a strong alkali to 
remove mepacrine degradation products. The aqueous 
phase is removed by aspiration and the ethylene' 
dichloride containing pure mepacrine remains.
After transference to a clean test tube a small 
amount of glacial acetic acid is added to stabilise 
and enhance the fluorescence. The blood mepacrine 
is determined by comparing the fluorescent intensity 
of the acidified ethylene dichloride extract of 
blood with that.of a standard prepared by the same 
extraction procedure from a stock aqueous solution 
of known strength. Small but fairly constant 
reagent blank readings are obtained with this method.. 
They are alv/ays subtracted from the standard and 
unknown.
Later, a Coleman Eluorimeter was available 
and its performance was compared with that of the 
Hilger Bluorimeter. Both instruments had adequate
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sensitivity for the range of concentration 
encountered in whole blood. The Coleman was 
much more sensitive but it tended to lose sensitiv­
ity over a period of a year, whereas the sensitivity 
of the Hilger remained more or less constant. But 
even then the Coleman was more sensitive than the 
Hilger. The loss of sensitivity was not due to 
discharge of the batteries. It may have been due 
to changes in the photocell or in the amplifier.
The reproducibility of blood mepacrines, 
gauged by comparing triplicate estimations from 
the same sample of blood, are shown in Table 3 (Vol.2 p3).
The difference in triplicate estimations
’ \from the same sample of blood was insignificant
over a concentration range of 66 to 286 ug. per
litre.- This finding, together with the high degree
of specificity and the excellent extraction recoveries
12reported by Brodie and Udenfriend, suggests that 
the method is reliable.
Blood Mepacrine and Malaria. — Blood was withdrawn 
for mepacrine estimation immediately before the
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daily dose of drug was given1, so that minimal 
daily levels were determined. The incubation 
period of malaria in the volunteers taking mep­
acrine varied from 9 to 21 days, but it was 
reasonably constant in each group of volunteers 
exposed to the same type and number,of infections.
The relation between blood mepacrine and the 
occurrence of malaria has therefore been examined 
by comparing the blood levels of the malarias in. 
each group within 24 hours of the onset of malaria, 
y/ith the levels of the other volunteers in the same 
group at the same .time.
The blood mex^acrine values of 12 volunteers 
y/ho' developed malaria, and those of comparable 
volunteers who escaped the disease, are shovm in 
Table 4 (7ol.2.p>4). If the blood mepacrines are 
compared group) by group, it will be seen that the 
levels in the malarias were always lower than the 
minimum levels of the others. The blood mepacrines 
of the 12 malarias ranged from 10 to 77 ug. per litre, 
the values of the others ranged from 100 to -680 ug.
per litre. It would therefore appear that a 
minimal daily blood-mepacrine level of 100' ug. 
per litre just before the onset of malaria was 
necessary to prevent the disease.
Typical blood mepacrine curves of 4 
volunteers■throughout the incubation period are 
shown in Graph 2 (Vol.2 p36). Two volunteers 
received a total dose of l.Og. mepacrine in 3 days 
at different times.in-the incubation period; one 
developed malaria* the second had no.reaction.
The other two volunteers were given O.lg. mepacrine 
daily for 20 days-beginning on the day of infection 
one- developed malaria, and the second had a temp­
erature of IGO0?. -12 days after infection but 
parasites were not found in the blood and the fever 
did not recur. The blood.mepacrines of the two 
malarias were less than the blood.mepacrines of the 
other two at the onset of the disease. . The levels 
on the.day of infection and for 6 days thereafter 
did not appear to have much influence on the 
subsequent course of events. The blood mepacrine
just before the onset of malaria decided whether- 
or not the disease appeared.
. These results- indicate that the prevention 
of malaria with mepacrine depends entirely on the 
concentration of the drug in the blood.
Blood lap.- crlne and ffever without Berasitaemia.• —
The relation of blood mexoacrine to fever without 
parasitaemia has been examined by contrasting the 
blood mepacrines of.the same volunteer before the 
onset of fever and after ft had subsided. Blood 
for me]?acrine estimations was taken when the 
temperature was normal. The results are shown 
in Table 5 (Vol.2 p5).
The numbers are small, but in general, the 
closer to the onset of fever that estimations were 
made the lower were the blood mepacrines, and 
conversely, the closer to the-day of subsidence o f - 
'fever that estimations were made the higher were 
the blood mepacrines. These findings suggest that 
fever without parasitaemia may have some influence 
on blood mepacrine. Evidence supporting this view
has been found in three other volunteers who develop­
ed malaria after mepacrine administration had been 
stopped
:Volunteer 1 . - When the temperature 
returned to normal after the first pealt of fever 
the blood mepacrine was 130 ug. per litre. Before 
starting treatment with mepacrine and after the 
temperature had reached a second and much higher 
peak,_the blood mepacrine had risen to 500 ug. per 
litre. The spontaneous rise in blood mepacrine 
coincided with the fever.
Volunteer 2 . - A first relapse of M.'T. 
malaria was treated with mepacrine (3.4g. in 7 days). 
A second relapse occurred 12 days after the last 
dose of mepacrine. The blood mepacrine at the 
onset of the 'second relapse was 13 ug. per litre, 
and the plasma mepacrine was 6 ug. per litre. Twelve 
hours later the temperature was 104°B., the blood 
mepacrine was 390 ug. per- litre, and the plasma 
mepacrine was 40 ug. per litre, though no mepacrine 
had'been given.
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Volunteer 5 . - . Two attacks of fever 
without parasitaemia were followed by an afebrile 
period that preceded the onset Of a frank attack' 
of -malaria. The blood mepacrine curve throughout 
the incubation period, together with data on infect­
ion, doses of mepacrine, and fever, are. shown in 
Graph 3 (Vol.2 p37). Fever was observed on three,
occasions. Parasites were not found in the blood 
despite careful search of thick and thin films 
during the first tv/o attacks, but they were found 
the third time that fever appeared. Blood, taken 
from the volunteer at the time of the first fever 
when no parasites were found, caused malaria after 
injection into another individual. Spontaneous
t
rises in the blood mepacrine v/ere found that coin­
cided with the first two attacks of fever, ,and 
following these rises', fever subsided. But after 
the blood mepacrine had fallen to a very low level, 
a frank attack of malaria developed.
■ \ A pronounced rise in blood mepacrine assoc­
iated with fever was observed in three volunteers.
This rise was spontaneous and occurred long after
mepacrine dosing had' "been, stopped so that drug 
administration v/as not responsible for the change. 
The relatively high■mepacrine content of tissues 
and cells suggests that the spontaneous rise in 
blood mepacrine may have resulted from:-
(1) a transference of mepacrine from 
tissues to the blood.
*
(2 ) an increase in the cellular elements 
of the blood, particularly leucocytes*
The magnitude' of the rise, the simultaneous
vincrea.se in the plasma mepacrine of one volunteer, 
and the fact that leucopenia is the usual finding 
-during malarial-fever, suggest that the increase in 
blood mepacrine v/as mainly'due to transference of 
mepacrine from the tissues. The cause of the rise 
is uncertain, but it may result from the diminution 
in alkali reserve that accompanies fever, as a small 
change in pH has been found to alter the partition 
of mepacrine in a simple protein-water system in . 
this way (Vol.2 p50). But apart from the precise
cause of the rise in “blood mepacrine, the nature of 
the change explains the occurrence >of fever without 
parasitaemia. If parasites are present in the 
blood when the concentration of mepacrine has 
fallen below the parasiticidal level, then the 
parasites may be able to proliferate-and cause 
fever'. . She increase in the blood mepacrine 
resulting from the fever may raise the level 
sufficiently to kill the parasites and so abort 
the attack of malaria. Ihus while cure of the 
attack of malaria ultimately depends on the tissue 
mepacrine, the prevention of fever depends entirely 
on the blood mepacrine.
Summary. - The chemotherapeutic action of mepacrine 
in falciparum malaria has. been found to be related' 
to some extent to dose of mepacrine but more precise­
ly to the blood concentration of the drug. DoseL ,
was an inferior chemotherapeutic index because it 
offered no explanation why some individuals developed 
malaria while others taking the same dose escaped 
the disease. Blood mepacrine. estimations on "ohe
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other hand, showed that those v/ho developed 
malaria invariably had lower blood levels than 
the others who- escaped the disease, and they also 
provided a r)Ossible .explanation for the occurrence 
of fever without parasitaemia. Por these reasons 
blood mepacrine has been employed to define the 
aim of the preventive treatment of falciparum 
malaria with mepacrine.
A frank attack of falciparum malaria did 
not develop in volunteers experimentally infected 
with sporozoites if the minimal daily blood mep­
acrine was 100 ug. per litre or more towards the 
end of the incubation period. fhe aim of prevent­
ive treatment may therefore be defined as the main­
tenance of a minimal daily blood-mepacrine level 
of 100 ug. per litre throughout the period of 
exposure to infection, and for one month thereafter 
to deal with infection contracted just before leaving 
the malarious area. possible methods of maintain­
ing this minimal daily blood-mepacrine level are 




THE. PHARMACOLOGY OP IlIEPACKINE
Mepacrine is a yellow basic acridine dye 
that is soluble in water to the extent of about 5 g. 
per 100 ml. at 37°C.* . It is stable in powder form 
but in aqueous solution it is'slowly broken down / 
to another compound that is almost insoluble in 
water.
The dye-properties of mepacrine are res­
ponsible for its unusual distribution in the human 
body. The mepacrine concentration of. tissues and 
.cells has been found to be much higher than the 
concentration in plasma. Por example, the concent­
ration in leucocytes was more than 400 times that of 
plasma and even in plasma 80 to 90 per cent is
lQprobably bound to protein. As a consequence of 
this distribution Shannon argued, that if mepacrine 
acts directly on malaria parasites, 'the free plasma 
water mepacrine is of fundamental importance
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che mo therapeutically and pharmacologically, because 
the plasma water mepacrine is in equilibrium with 
tissues, cellar, proteins, and malaria parasites 
whether they are intracellular or in the_ plasma 
water.
v
Since it is not practical to estimate 
/plasma water mepacrine, blood mepacrine v/as taken 
as a possible index to investigate the chemother­
apeutic action of the drug. Two important
observations were made that have an important
*
bearing on the pharmacology of the drug. They 
were:-
.1. - The limitations of dose and the 
advantage of blood mepacrine#as a chemotherapeutic 
index of the action of mepacrine in falciparum 
malaria.
2. - The rise in blood mepacrine during . 
fever, possibly resulting from the transference of 
the drug from tissues to the blood.
The limitation of dose as a chemotherapeutic
- 28 -
index has made it necessary to define the 
relationship of hlood mepacrine to dose, route 
of administration, and period of administration. 
Preliminary investigations on the degradation of 
mepacrine in the body have also been carried out 
and the relation of blood mepacrine to urinary 
mepacrine and plasma mepacrine has been investigated.
The rise in blood mepacrine observed during
fever in volunteers infected with falciparum malaria
may result from the transference of mepacrine from
.'tissues to the blood. This implies an alteration
in the tissue:blood partition of the drug. Intrinsic
factors apart from- dose that alter blbod mepacrine
*may therefore be of great importance chemotherapeut- 
.ically. Direct investigation of the effect of such 
factors on the tissueiblood partition v/as not pract­
ical but the basic principles regulating the part­
ition of mepacrine in a simple proteinswater:mepacrine 
system have been studied.
The relation of blood mepacrine. to dose, 
route of administration, and period of administration;
and the relation of urinary mepacrine to dose and 
period of administration will first he described. 
Then degradation of mepacrine in blood, plasma, 
urine, and faeces will be considered and will' be 
followed by an examination of the factors that 
influence the proteinswater partition of the drug, 
finally the interrelations of blood, plasma, and 
urinary mepacrine will be discussed..
Blood Mepacrine and Dose. - The relation of blood 
mepacrine to dose has been investigated by giving 
groups of healthy volunteers different doses of 
•the drug by mouth, over the same period, and estim­
ating the blood mepacrines at comparable intervals. 
The volunteers were all healthy soldiers taking the 
same diet and were confined to bed during the five 
days of the investigation. Mepacrine was given in 
tablet form and a half pint of water was taken with 
each dose. The dosage' regimes and the number of 
individuals employed v/ere as follows:-#
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Regime Dose of Mepacrine ■ No.of Volunteers
1 Day 1 - Initial dose 0.6g.
Days 2 to 5 inclusive 0.3g. daily 8
Total dose l*8g. in 5 days
2 Day 1 - Initial dose O.gg.-
G.3g. at 4 hrs. and 
0.5g. at 12 hrs. 7
Days 2 to 5 inclusive 0.6g. daily 
Total dose 3.4g. in 5 days
3 Day 1 - 0.2g. 4 hrly, 6 doses
Day 2 - Q.2g. 6 hrly, 4 doses
Days 3 to 5 inclusive 0.2g. 12 hrly, 
Total dose 3.2g. i n -5 days
The frequency of dosing and the total 
amount of mepacrine given in 5 days v/as different 
in the three.regimes. In regime 1, single daily 
doses were given throughout. In regime 2, 
increasing daily doses were given in'the first 12 
hours, thereafter single daily doses were given on 
days 2 to 5. The single daily doses in regime 2 
v/ere tv/ice the daily doses given in regime 1. In 
regime 3 an attempt was made to give approximately 
the same total daily dose as in regime 2, hut in 





Regime 1 (lU8g. in 5 days). - Blood mepacrines 
were estimated at 4, 12, 24, 48, 72, 96, and 120 
hours after the first dose. There were marked 
variation in the levels of different individuals 
taking the same dose, hut the group mean values 
provided a good index of the trend in each indiv­
idual. The group mean hlood mepacrines at the 
above times were:- 213, 173, 84, 179, 225, 245, 
and 264 ug. per litre.
Regime 2 (5.4g. in 5 days). - Blood mepacrines
'were estimated at 4, 12, 25, 48, 72, 96, and 120 
hours after the first dose. As in regime 1, 
marked differences .in the individuals' values were 
observed, but the group mean level reflected the*
trend in each volunteer. The group mean value's 
at the above times were:- 105,'-246, 384, 415, 560, 
679, and 873 ug. per litre of blood.
Regime 3 (3.2g. in 5 days). - Estimations were
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made at 8,„ 16, 29, 53, 77, 101, and 125 hours after 
the initial dose. The corresj)onding group mean 
blood mepacrines were;- 131, 363, 387, 618, 604,
,665, and 858 ug. per litre. As in the previous 
two. regimes, these values 7/ere indicative of the 
trend in each individual.
hetail-ed results are given in Table 6 (Vol.2 p6).
Group mean blood mepa-crines for the three 
regimes are shown in Graxoh 4 (Vol.2 p38). In 
regime 1, a total dose of 1.8g. mepacrine was given 
in 5 days and the group piean blood mepacrine curve 
24 hours after each dose was uniformly lower than 
the curves for regimes 2 and, 3 in which total doses 
of 3.4 and 3.2g’. mepacrine were, given respectively.
This suggests a direct relationship betT//een blood 
mepacrine and dose in the initial days of dosing.
In regimes 2 and 3 approximately the same 
total dose v/as given in 5 days but the frequency 
of dosing v/as different. The values for both 
regimes 24 hours after total doses of 3.4 and o.2g.
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were 873 and 858 ug. per litre of "blood respect­
ively. That is, for practical purposes the •
"blood mepacrines were the same, and since the 
differences in the mid-parts of the curves are 
accounted for "by differences in the total dose 
given, frequency of dosing would seem to he less 
important than the total dose in determining the 
minimal daily blood mepacrine level. However, 
frequency of dosing may be important in the .first 
day,of dosing when it is desirable that a particular 
blood-mepacrine level should be quickly attained
and then maintained. In regime 1, a single dose-/
%of mepacrine was given on the first day, the group 
mean blood inepacrine at 4 hours v/as 213 ug. -per 
litre and at 24 hours it had fallen to 84 ug. per 
litre. In the other two regimes, more frequent 
doses were given and the levels progressively 
increased during the first 24 hours. -
Urinary Mepacrine and Dose. — The total amount 
of mepacrine excreted in the urine of .the. volunt­
eers taking mepacrine dosage regimes 1, 2, and 3
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has been estimated. In regime 1 (a.8g. in 5 days), 
urinary estimations were made on samples collected,
0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours after 
g the first dose and th.erea.fter at intervals of 
24 hours until the end of the investigation on day 5. 
In regime 2 (3.4g. in 5 days), estimations were made 
on samples collected at 0 to 8, 8 to 16,. and 16 to 
24 hours after the initial dose and then at'24 hour 
intervals until day 5. In regime 3 (3.2g. in 5 days), 
urinary mepacrine was estimated in samples at 0 to 
4, -4 to 8, 8 to 12, 12 to 16, 16 to 20, and 20 to 
29 hours after the initial .dose and then at intervals 
of 24 hours until the end of the investigation on 
day 5.
The results are shown in fables 7, 8, and 9 
(Vol.2. p?,8 & 9) and have been expressed as the 
total amount of mepacrine excreted in each period.
The variation - in urinary mepacrines of individuals 
taking the same doses of the drug v/as considerable 
in each of the three regimes, but the group mean 
urinary mepacrine provided a reliable index of the
general trend in each individual. The group mean 
u r i n a r y  mepacrine curves are shown in Graph 5 (Vol.2 p39).
The curves for regimes 2 and 3, in which the total
dosage was approxiipately the same, were almost
identical. Both were much higher than the curve
for regime 1 in which the total dosage v/as a little 
more than half that of the other two regimes. Urinary 
mepacrine would therefore seem to he related to the 
amount of drug given in the early days of dosing,
■and because of the similarity in urinary mepacrines 
'of regimes 2 and 3, total dose v/ould also apioear to 
be more important than frequency of/dosing in deter­
mining the urinary excretion of the drug..
Comparison of Tables 6 to 9, and of (Graphs 
4 and 5, reveal that the' minimal daily blood mep­
acrine is directly related to the amount of mep­
acrine -excreted in the urine in the previous 24 
hours.. In each regime, the range of variation in 
blood' mepacrine and in urinary mepacrines was 
considerable, but individuals with high blood mep­
acrines usually had high urinary mepacrines and
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vice versa. This strongly suggests that the 
same cause is responsible for the variation in the 
blood and urinary mepacrines of individuals taking
the same doses of the drug.
Blood Mepacrine and Route'of Administration. The 
blood mepacrine after administration of the drug 
by different routes has been investigated. The 
same dose v/as given as a solution containing 0,2g.
i
mepacrine hydrochloride in 10 ml. sterile distilled 
water to groups of 4 to 6 healthy volunteers by 
mouth, and by rectal, subcutaneous,'intramuscular, 
and intravenous injection.. Blood mepacrines were 
estimated at intervals during the following 24 hours. 
In addition, 'two O.lg. mepacrine hydrochloride tab­
lets were given by mouth with half a pint of water 
to another group of volunteers to compare blood 
mepacrines after oral administration of tablets 
and mepacrine in solution. The results are shown 
in Tables 10 to 15. (Vol.2 plb to 12).
The blood mepacrines after rectal, subcut­
aneous, intramuscular, and intravenous injections
were for practical purposes the same. The blood 
mepacrines after oral administration of tablets, 
differed from parenteral and rectal administration 
in three important respects
(1) in the time required to reach a peak, 
concentration.
(2) in the magnitude of the peak.
(3) in the variation between individual 
blood mepacrines.
The group mean values in Graph 6 (Vol.2 p40) 
show the difference between parenteral and oral 
dosing in two 'respects - namely, in the time required 
to reach a peak and in the magnitude of the peak 
attained. Group mean peak concentrations of 565 • 
and 617. ug. per litre were reached in 15 minutes 
after-intramuscular and subcutaneous injections 
respectively. A group mean peak of 632 ug. per 
litre was reached in 45 minutes after rectal inject­
ion, and a group mean peak level of 226 ug. per 
litre was attained in the same time after oral 
administration of mepacrine in solution. A group
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mean peak of only 162 ug. per litre was reached 
in 2-J- hours after oral administration of tablets.
The blood-mepacrine levels fell, rapidly 
at first then more slov/ly, after attainment of 
peak concentrations by mepacrine injections. 
Minimal values were usually observed 24 hours 
after the dose. 'The group mean blood'mepacrines 
at 24 hours after tablets by mouth, rectal' inject­
ion, subcutaneous injection, intramuscular inject­
ion, and intravenous injection were 54, 47. ,t 60, 92, 
and 102 ug. per litre respectively. That is, the 
post absorptive blood mepacrines were higher after 
intravenous and intramuscular injection than after 
oral adriiini strati on of. tablets.
The variation in the individual blood-. 
mepacrine values v/as more pronounced after tablets 
"by mouth than'after oral "administration of a mep­
acrine solution and injection by the other routes.
The' delay iii reaching a peak concentration
following the administration of tablets by mouth 
> - •
is partly explained by .the time required for
solution of the tablets, hut as the tablets employed
were not coated, and as they disintegrated readily
in water, it is not likely that incomplete solution
of the tablets v/as responsible for the differences
in blood mepacrines that were observed. Diminished
absorption due to other censes seems a more probable *
explanation. But apart from consideration of the
\
cause of the difference in blood mepacrine following 
oral and parenteral administration, the observation 
may have a practical application in the treatment 
of malaria, particularly in seriously ill patients 
in whom a rapid chemotherapeutic effect is desired. 
With this possibility in view, the blood mepacrines • 
after repeated parenteral injections, and after 
combined oral and parenteral administration have 
been defined in healthy volunteers who remained 
in bed during mepacrine administration.
Repeated Parenteral Injections. - Four healthy 
volunteers were given an initial subcutaneous 
injection of 0.2g. mepacrine hydrochloride in 10 ml.
distilled-water followed by two O.lg. injections by
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the same route, two hours and five hours later % 
The blood mepacrines at intervals throughout the 
24 hours after the first injection are shown in 
fable 16 (Vol.2 pl3).
Peaks in the group mean blood mepacrine 
of 688, 947,- and 606 ug. per litre were observed 
fifteen minutes after each injection. A group 
mean value of more than 200 ug. per litre v/as 
maintained' during the first 9 hours and at 24 
hours the level had fallen to 117 ug. per litre.
Combined Oral and Parenteral Administration.. - * 
Another eight volunteers were given an initial dos 
of Q.2g. mepacrine hydrochloride intramuscularly 
and 0..2g. (2 tablets) by mouth. Six hours, 14 
hours, and 24 hours later, single doses of 0.4g.
(i tablets) were given by mouth. A total dose of 
1.6g. mepacrine v/as given to each individual in 
24 hours. The’ resulting blood mepacrines at 
intervals during the 72 hours after the initial 
dose are shown in.Table 17 (Vol.2 pl4).
• The initial 0.2g. oral dose did not have
much influence on the group mean blood mepacrine 
during the first six hours (Of. Tables 15 .and 17 
Vol.2 pl2 <T 14), but at 12 hours, after a total 
dose of 0.3g. mepacrine, the group mean value 
reached the very high level of 1798 ug. per litre 
and then fell relatively slowly to 325 ug. per 
litre at 72 hours.
Maintenance of a steady blood mepacrine 
by parenteral injection alone is difficult, because 
o.f the rapid rise to, and the rapid fall from peak 
levels. However, the rate of fall is influenced 
by combined oral and parenteral treatment, but 
before this action comes into play very high temp- 
'orary levels may be reached. Parenteral injection 
seems in some unexplained way to potentiate absorpt­
ion of mepacrine from the gut. This may explain , 
why serious toxic effects have been so frequently
reported sifter combined oral and parenteral admin—
. . . . .  2 ist; rat ion.
Blood and Urinary Mepacrine and Duration of Dosing. — 
The blood and urinary mepacrines -have been defined
after administration of the drug for 25, 76, and 
86 days to three groups of healthy volunteers who 
were carrying out light duties. Dosage regimes 
were chosen to investigate the effect on blood 
and urinary mepacrine of a preliminary loading 
dose of the drug, and also to. compare daily doses 
of O.lg. with weekly doses of 0.5g. The'doses 
given and the number of volunteers employed were 
as follows:- *
Regime' Dose of Mepacrine Ho. of Volunteers Period
days
4 O.lg. daily 11 86
5 Day 1 O.lg. 8 25
Day 2 O.Sg.
. Day 3 O.Sg.
"Days 4 to 25 O.lg. daily
6 Day 1 O.lg. 6 76




Day 11 - 0.5g. and then
O.Sg. at weekly intervals 
until Day 76.
In regime' 4 (O.lg. daily for 86 days), the 
taking of mepacrine -was carefully supervised from
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Monday -to Saturday each week. On Sundays each 
individual v/as responsible for taking the drug 
himself and all hut one volunteer forgot to take 
the drug on 1 to' 5 occasions during the invest­
igation.' In regime 5, it was possible to ensure 
only that each individual took the drug in the 
presence of a witness who attested in a diary that 
the dose had been-taken. fhere v/as no reason to 
believe that the drug was not taken as prescribed. 
In regime 6, dosing was carefully supervised 
throughout the investigation.
R egime 4 . (O.lg. daily). - Blood samples.were 
.taken for mepacrine estimation about every third 
or fourth day. Samples were withdrawn immediately 
before the daily dose so that minimum daily blood 
mepacrine levels were estimated.. Corresponding 
urine samples v/ere collected for mepacrine estimat­
ion over the three hours immediately preceding.the 
daily dose.' The individual results and the group 
aiean blood and urinary mepacrines are shown in 
Graphs 7 and 3 (Vol.2 p41 & 42). Mepacrine dosing
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and “blood and urinary estimations were continued 
for a total period of 140 days in 4 of the 11 
volunteers.
flie group mean blood mepacrine increased 
to 167 ug. per litre on the 15th day of dosing, 
then it fell to 109 ug. per litre* on the 25th day. 
The fall v/as followed by a sharp rise to 215 ug. 
per litre on the 29tli day. The level again fell, 
slowly to 195 ug. per litre on the J39th day'and 
then more rapidly to 94 ug. per litre on the 53rd 
day. Thereafter the blood mepacrine v/as much 
more stable and varied betv/een 100 and 120 ug. per 
litre until the end of the main investigation on 
day 86. The same level was maintained until day 
140 in 4 of the 11 volunteers in whom observations 
v/ere continued.
The group mean urinary mepacrine curves 
expressed either as a concentration (mg. -per litre) 
or as the total amount excreted in 3 hours (mg.), 
were for practical purposes the same. Both 
progressively increased to reach peah values during
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the-first 15 days of dosing. Then,- after consider­
able fluctuations, the general tendency v/as for the 
urinary mepacrine to decrease progressively until 
day 3<f v/hen a relatively stable level was reached, 
and maintained#
Hie changes in blood and urinary mepacrine 
after prolonged administration of the drug were 
essentially the same. In general there v/as a 
build up to peak concentrations, then a fall -to 
stable levels that were about half the peak values 
(Graph 9 Vol.2 p43). .
Regime 5 . (loading, dose l.Og. then O.lg. daily
I
until day 25). - Unlike the other volunteers 
those employed in this investigation were billeted 
in another hospital and other arrangements had to 
be made for collection of blood and urinary samples. 
Blood for mepacrine estimation was taken 20 to 24 
hours after a dose and the mepacrine concentration 
in the corresponding night urine v/as determined. 
Estimations were made over a period of 121 days, 
that is for 96 days after the last dose of mepacrine.
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Detailed results are shown in Tables 18 and .19 
(Vol.2 pl5 & 16). The group mean blood and 
urine mepacrines* are shown in Graph 10 (Vol.2*p44).
The group mean blood mepacrine reached • 
a peak of 516 ug. per litre on day 4 -.the day 
after the 0.6g. dose. It then fell to 328 ug. 
per litre on the day 11 and remained at this level 
until day 17. . Then the level rose to 479 ug. per 
litre on day 24. On day 29, that is 4 days after 
dosing had stopped, the level v/as 387 ug. per litre, 
and on day 37 it had fallen to 151 ug. per litre.
.An appreciable rise to 270 ug. per litre'was recorded 
■on day 53, and thereafter the level fell progressively 
to 41 ,ug. per litre.on day 121.
The concentration of mepacrine in the night 
urine reached a peak value on day 11, and then fell 
sharply. A second peak was reached on day 29 and 
then the level progressively fell until the end of 
the investigation on.day 121.
In general the changes in blood and urinary 
.mepacrine were of the same nature throughout the
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investigation. The persistence of mepacrine in
blood and urine long after dosing had stopped is' '■
%
noteworthy.
Regime 6 . (Loading dose of 1.5g. in 5 days; then
0.5g. weekly).- - The blood mepacrine was-estim­
ated 24 hours after the daily dosing period and 
then immediately before each weekly dose, so that 
minimum blood levels were determined. The urinary 
mepacrine was estimated on two consecutive days 
each week. The first estimation was made on the 
urine passed during the three hours immediately, 
preceding the weekly dose, and the second estimation 
on a three hours’ sample of urine from the 21st to 
the 24th hour after the weekly dose. The intention 
was to determine.the post absorptive minimum and 
maximum urinary mepacrines each week. The results 
are given in Tables 20 and 21 (Vol.2 pl7 & 18).
The group mean blood and urinary mepacrines are 
shorn in G-raph 11 (Vol.2 p45).
The group mean blood mepacrine was 184 ug. 
per litre on day S after a loading dose of 1.5g.
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in the previous 5 days. It then fell to 62 ug. 
per litre-on the 27th day and' rose to 117 ug. per 
litre on the 34th day. Thereafter the level 
remained 'comparatively stable at about 100 ug. per 
litre.
The urinary mepacrines, estimated 21 to 
24 hours after the weekly dose (post-absorptive
s ' ' .maximum level;, increased from day 14 to day 42, 
and then stabilised. The urinary mepacrines, 
estimated on a three hours* sample immediately 
preceding the weekly dose (post-absorptive minimum 
level), increased from day 13 to day 27, and then 
decreased to reach a stable level on day 34. The 
difference in post-absorptive maximum and minimum 
levels was slight after the first weekly dose. It 
was greater after the third weekly'dose-and contin­
ued to increase until the 5th weekly dose. There­
after both urinary levels were relatively stable.
* When the group_ mean^ minimum and maximum 
urinary mepacrines were low and when the difference 
between them was slight, the group mean blood
mepacrine fell. When "the difference in the 
urinary levels increased, the blood.mepacrine 
started to-rise. When the difference in urinary 
levels was pronounced hut constant, the blood 
level was stable. These findings suggest that 
only a small amount of the first three weekly 
doses of mepacrine was absorbed, or that the rate 
of degradation of mepacrine within the body had ' 
temporarily increased when the first three' weekly 
doses were given.
Blood and urinary mepacrines after-admin- 
istration of different doses of the'drug for 05, 
76, and 86 days have been defined. In the. two
X&jL
regimes thatAdrug was given for prolonged periods, 
three distinct phases in the group mean blood and* 
urinary mepacrines have been observed
1. — an initial phase that may be termed
the build up period, in which blood and urinary
mepacrines ran in parallel curves to reach peak
0
values. . The duration of the build up period, 
and the peak levels attained, depended on uhe
amounii of mepacrine given. When O.lg. mepacrine
was given. daily with and without a preliminary 
loading dose, a higher peak was reached in a 
shorter 'time with the loading dose than without 
it (Cf. Graphs 9 and 10 Vol.2 p4 3 '& 44).
2 . -  an intermediate phase in which 
the blood and urinary mepacrines both fell from 
the peak levels to minimum values. During this 
time marked fluctuations in blood and urinary 
mepacrines, even from.day to day, were observed; 
and though the general tendency was for both 
levels to fall, the parallelism that had previously 
been observed was not always apparent. The fall 
in both blood and urinary mepacrine occurred in 
spite of continuous mepacrine dosing, so that
dose had little or no influence on the changes 
during this temporary unstable phase. (Graphs 9 
and 11 Vol.2 p43 & 45).
3. - a later phase in which the. blood 
and urinary mepacrine curves v/ere similar and
reached comparatively stable levels that were 
appro jiimauely nali the peak values. fluctuations 
in ootlq blood and urinary mepacrines were not so 
pronounced as in the previous phase and there was 
much less variation in individual results. * The- 
difference in the group mean blood mepacrine 
after O.lg. daily and O.og. weekly was slight,
■ suggesting that total dose-is more>important 
than frequency of dosing in maintaining the 
subsequent stable level.
The simultaneous fall in blood and urinary 
mepacrine after the peak levels had been reached 
was the most important change. ihat it occurred 
in two investigations, carried out at different 
times with different regimes, suggests tha.t it was 
more than a chance observation. It seems highly 
probable that a powerful factor regulating blood 
and urinary mepacrine comes into play when the 
drug has been given for prolonged periods. More­
over, the changes in blood and urinary mepacrine
likely that they are due to fhe same cause.
Yuriation in absorption from the gut or variation 
in the rate of degradation within the body seemed
the most•likely explanations. An attempt to 
determine their relative importance had been made 
by estimating faeoal mepacrines of groups of 
volunteers during the build up’ period, and during 
the later stable phase when blood and urinary 
mepacrines were about half the peak values. It 
would have been erable 'to have estimatedi
faecal mepacrines in the, same group at different 
times, but the supply of volunteers to take the 
drug for long periods was limited and so observat­
ions had to be made on two different groups.
Before reporting these investigations it is necess
ary to refer to the method of estimating mepacrine 
in faeces.
Estimation of ffaecal Mepacrine. - The stool 
was collected in a tared litre beaker and 
-weighed/ Anhydrous sodium sulphate was 
added to dry the faeces, and the beaken +■. 
faeces + sodium su.lpha.te was weighed o-gain. 
i’he contents of the* beaker were then turned 
into a lar-e- mortar and vround and mixed for
*“ o  ^
20 minutes. The resultant mixture was like 
a very fine dry sand. 5.0g. of the mixture 
were placed in a stoppered graduated 100 ml. 
cylinder and distilled water added to the 
100 ml. mark, i’he flask was stoppered, and 
shaken vigorously for 5 minutes and then 
placed on the bench to allow the insoluble 
materials t o separate.
Five ml. of the supernatant solution 
were taken, and the mepacrine concentration 
estimated in the same way as in urine.
Two major factors required investigation 
with this method of dealing with faeces. One, 
whether 5.0g. of the faeces - anhydrous sodium 
suliliate mixture was a representative sample of. 
the whole mixture; and two, whether extraction 
recoveries were Adequate and were influenced by 
the time faeces were allowed to stand before 
estimation. These problems were examined by 
adding known amounts of mepacrine to the faeces ■
of individuals who had never taken the drug. The 
menacrine content of duplicate and triplicate
-1- i
samples of the stool was then estimated by the 
method outlined above. This practice was carried 
out at intervals of b, 24-, 48, and 72 hours after
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the addition of 50 mgm. mepacrine to the stools
of three individuals who had never taken the
drug. The' results are shown in fable 22 (Vol.2 pl9).
The difference in the estimations of 
duplicate and triplicate samples from the same 
stool, was sufficiently small to indicate that 
the mixing procedure was adequate and that 5g. 
of the sodium sulphate-faeces mixture was a represent­
ative sample.
The rate of disappearance of mepacrine 
from the three stools was rapid and was approx­
imately the same for each stool. At 3 hours, * 
an average of 70$ of the added me|)acrine was 
recovered; at 24 hours, 48$; at 48 hours, 18$; 
and at 72 hours, 14$. Shat is, the more mepacrine - 
present the more rapid the rate of disappearance. 
Disappearance of mepacrine has been interpreted 
as being mainly due to degradation 'of the drug by 
faeces. This striking finding made it necessary 
to estimate the mepacrine content* of faeces aŝ  
soon as possible after they had been passed, but
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even then 110 indication of the" amount of mepacrine 
degraded within the bowel could be obtained. 
However, since the rate of degradation of mepacrine 
in different specimens of faeces seemed to he fair­
ly constant, it was considered worth-while estim­
ating faecal mepacrines of two groups of Volunteers 
during the “build-up of blood mepacrine, and during
the later stable phase provided that the faecal 
mepacrine estimations of both groups were treated 
in the same way.
Faecal Mepacrines. - In view of the rapid 
disappearance of mepacrine from faeces after' they 
have been passed, faecal mepacrines were estimated 
whenever possible within 3 hours of the time of 
defaecation. This was not always practicable 
and a few estimations were made 12 - 16 hours 
after'-defaecation. . '
The faecal mepacrines of four volunteers, 
during the iirst 6 days of taking O.lg. mepacrine 
daily were estimated and compared with those of 
seven - other volunteers who had taken the same dose
of the drug for the previous 62 days. The 
seven volunteers belonged to the group of 11 
men whose' blood and urinary mepacrines were 
defined over a period of 86 days. At the time 
the observations were made the group mean- blood 
and urinary levels were stable and had fallen 
to about half the peak values.
The total mepacrine in the faeces of the 
four men'during the first six days of dosing was 
8.5, 11.8, 20.0, and 41.1mg. The total faecal 
mepacrines of the other seven men for a similar 
period were:- 114.6, 119.4, 131.8, 146.3, 167.0, 
167.0, and 172.2mg.. These'values do not repres­
ent absolute faecal mepacrines, but as the invest­
igations were carried out under •comparable condit­
ions, the uniformity of the individual results aiid
the marked difference in faecal mexDacrines .of the#
two groups strongly suggest that more mepacrine is 
excreted in the faeces during the late stable phase 
in blood and urinary mepacrine, than during the 
build up period. The simultaneous fall in both
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"blood and urinary mepacrine -to about half the 
peak levels, together with an increase in faecal 
mepacrine'suggests that diminished absorption of 
mepacrine from the gut is at least partly respons­
ible for the fall. The cause of diminished 
absorption,is still obscure, but an important clue 
was obtained in the development' of a suitable 
method for estimating mepacrine in faeces. In 
this \York mepacrine added to stools rapidly dis­
appeared. It is reasonable to presume that similar 
changes occur within the gut, so that, diminished 
absorption may be in part due to degradation by . 
-intestinal contents. The differences in faecal 
mepacrines at different times in the administration 
of the drug may be - accounted for by the fact that 
during the build up period tissue meiDacrine is 
progressively increasing until a peak value is 
reached. The attainment of a peak tissue mepacrine 
coincides with peak blood and urinary values; and 
then tissue, blood, and urinary mepacrines are in , 
equilibrium with the dosage regime. Doses of
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mepacrine given after this equilibrium come in 
contact v/ith an intestinal mucosa with which 
they are already'in equilibrium, so that less 
mepacrine is absorbed and a greater proportion 
of the' dose remains in the gut. But the longer 
that mepacrine remains in the gut the greater is 
the amount degraded by the intestinal contents.
The fall in blood and urinary mepacrines to stable 
levels of about half the peak value may therefore 
be largely due to diminished absorption resulting 
from this chain of events.
Mepacrine Bxcretion. - Blood and urinary mepacrines 
were estimated in addition to the faecal mepacrines 
of the 7 men who had taken daily doses of O.lg. 
mepacrine for '62 days before the investigation. The 
results are shown in Tables 23 to 29 (Vol.2 p20 & 21).
In tv/o volunteers it was not possible to 
estimate the 24 hours1 urine every day but in the 
remaining five the total mepacrine. excreted in the 
urine in 6 days by each individual varied from 15.6 mg. 
to 32.1 mg. The group mean urinary mepacrine for the
6 day period was 24 mg.. The total faecal mepacrine 
of the same volunteers in 6 days ranged from 119.4 mg. 
to 151.2 mg. and the group mean was 138.mg. That 
is, the total group mean mepacrine excreted in 6 days 
in urine and faeces was 162 mg.. But' the total' 
dose given in this period was 600 mg., and the group 
mean blood mepacrine was practically constant, so 
that the remaining 433 mg. probably represents the 
total amount of mepacrine degraded in 6 days.
Similar investigetions were carried out on 
another volunteer taking weekly doses of 0.5g. 
-mepacrine. Blood, urine, and faecal mepacrines 
were estimated for 3. days before and for 5 days 
after the weekly dose. Experimental conditions
were particularly good because stools of approx­
imately the same weight were obtained about the 
same time each day throughout the investigation 
and estimations were made immediately after they - 
had been passed.- The results are shown'in Table 30
(Vol.2 p22).
The blood mepacrine was fairly stable
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throughout the investigation.. The total 'mepacrine 
excreted in the urine in one week was about 14 mg. 
and the total faecal mepacrine in the .same period 
was 146 mg.. /That is, 160 mg. of the total weekly 
dose- of 500 mg. were excreted in urine and faeces, 
but since the blood level was practically constant 
the remaining 340 mg. was probably'degraded.
The relationship between the total urinary 
mepacrine and the total faecal mepacrine over the 
period of investigation is* noteworthy. * In the 5 
men taking O.lg. mepacrine daily from day 63 to 67 
inclusive, individuals -with a low total urinary 
mepacrine had low total faecal mepa-crines, and vice 
versa. , In the volunteer taking 0.5g. weekly the 
relationship was even more, striking. The curves 
for urinary and faecal mepacrine were practically 
parallel (Graph 12 Vol.2 p46). These findings 
"suggest that when the blood mepacrine is stable, 
the urinary and faecal mepacrines are proportional 
iso one another.
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Bl-ood, Urine, and Faecal Mepacrines. - The 
relation between blood, urine, and faecal mepacrines 
has been examined in the 7 men taking O.'lg. mepacrine 
daily for the previous 62 days. Complete results' 
were obtained in 4- men over the 6 days' balance 
period. The mean blood mepacrine.of each, man
during this period has been compared with the total
/
urinary and faecal mepacrine over the same period. • 
The following results were obtained
Mean Blood Total Urinary Total Faecal
Mepacrine Mepacrine Mepacrine
ug. /litre mg. mg.
1 82 15.6 119.4
2 99 22.9 139.0
3 111 22.9 146.0
4 156 32.1 151.2
The*'urinary and faecal mepacrine tended to 
increase as the blood mepacrine increased. In other 
words the blood mepacrine, and by inference the tissue 
mepacrine, controls the excretion of the drug in urine 
and faeces after prolonged dosing.
■Mepacrine D epro.dation.‘ - When blood and urinary
HiQDacrines were stable after daily doses of O.lg.
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ox the drug, an average of about 30$> of the total 
dose given in 6 days was recovered from urine and 
faeces,- she remaining 7Ov/o was unaccounted for. But 
as the blood level './as constant, the tissue level 
may also be presumed to be constant,, so that 70°/o 
of the dose was probably degraded. Degradation 
of mepacrine may therefore be important pharmacolog­
ically.
When mepacrine degradation is considered, 
it is necessary to distinguish clearly between 
degradation within the bowel, and degradation in 
the tissues of the body, because mepacrine degraded 
in the intestine has had no opportunity to exert, 
a chemotherapeutic action ‘whereas mepa.crine degraded 
in the .body has had this opportunity. An indication 
of the importance of degradation in the bowel is 
probably provided by the rate of degradation of the 
drug in faeces, but it is still impossible to measure 
degradation of the drug in the body. Investigations 
of the rate of degradation in incubated blood, plasma, 
end urine .were Garried out to explore possible methods
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of assessing degradation of mepacrine in the body.
Degradation of Mepacrine in Blood. - A volunteer 
was given 1.5g. mepacrine in 3 days. A large 
volume of blood was taken 24 hours after the last 
dose of the drug and was divided into 5 ml. samples 
that were placed in glass stoppered extraction 
bottles. Precautions we re taken to avoid bacterial 
contamination of the blood. The extraction bottles, 
were placed in an incubator at 37°0. Blood mepacrine 
of duplicate samples was estimated soon after with- . 
drawal of blood, and then at 24 hour intervals for • 
the next 8 days. The results are shorn in fable 31 * 
(Vol.2 p23)' and in Graph. 13. (Vol.2 p47).
fhe initial mean blood mepacrine was 575 ug. . 
p-err litre. fhe mean values at 24 hour intervals- 
for the next 8 days were 410, 320, 250, 200, 200,
,160, 160, and 130 ug. per litre. As with faecal 
mepacrines, the rate of degradation was rapid at 
first and. then it slowed1 down as the total amount 
of mepacrine diminished.
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Depredation of Mepacrine in-'Plasma. - Blood from 
a volunteer wlio had been given 1.5g. mepaorine in 
3 days was taken 24 hours after the last dose of 
mepacrine and the plasma was separated immediately.
It v/as then divided into 5 ml. samples in sterile 
extraction battles and incubated at 37°G. Care 
was taken to avoid bacterial contamination during 
the separation and sampling of the plasma. Plasma 
mepacrine estimations were made soon after withdrawal 
of blood and at intervals during the next week, fhe 
results are shown in fable 32 (Vol.2 p24). fhe 
initial plasma mepacrine was 120 ug. per litre and- 
the final value 7 days later was 80 ug. per litre.
Degradation of Mepacrine in Urine. - A known 
amount of mepacrine in solution was added to the 
urine of a healthy subject. Dive ml. samples were 
then added to' sterile glass stoppered extraction 
bottles that were placed in an incubator at 37°C. 
Urinary mepacrine was then estimated at 24 to 48
hour intervals during the following week. fhe 
results are shown in fable 32 (Vol.2 p24). fhe
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initial urinary mepacrine was 10.2 mg. per litre5 
one week/later it was 9.5 mg. per litre.
Degradation of Mepacrine in faeces. - When 50 mg.
%mepaorine were added to faeces, the amount of mep­
acrine recovered during the next three days progress­
ively fell. ' The fall v/as considered to "be mainly 
due to degradation of the drug in faeces (p.53). 
further investigations after adding 10 to 500 mg. 
mepacrine to the stools of two other healthy 
volunteers have confirmed-the previous findings, 
but it has also been found that degradation 
depends on the amount of, mepaorine'in the faeces. 
Degradation was minimal when 10 mg. mepacrine were 
added to stools, it" was maximal when 50 mg. were 
added; and it was minimal again when 100 mg. to 
500 mg. were added. (Table 33 "Vol.2 p25). That 
is, the general shape of the curve for degradation 
of mepacrine in faeces in relation to the amount of 
drug added resembles an- inverted ,,U ,f, the tips of 
the two limbs representing 10 mg. and 100 mg. 
respectively, and the highest point in the bend
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corresponding with. 50 mg. This suggests that 
degradation of mepacrine results from enzyme 
action. Small amounts of mepacrine may not he 
degraded because of strong physico-chemical affinities 
of the mepacrine-faeces mixture. Large amounts 
may not "be degraded "because of ""blockage" of the 
enzyme system responsible for degradation of the 
drug.
Mepacrine is degraded by blood, plasma, 
urine, and faeces. The rapid rate of degradation 
in blood and faeces supports the view that degrad­
ation of mepacrine is important in determining the 
blood and tissue' mepacrine levels after the drug 
has been given for prolonged periods. But as the 
excretion of mepacrine is dependent on the blood 
and tissue mepacrine levels, the amount of mepacrine 
degraded is therefore proportional to the amount of 
mepacrine absorbed, if constant blood and tissue 
levels are maintained. In other words, if absorption 
of mepacrine is constant, degradation of the drug 
may be assessed by changes in the blood and tissue 
meoacrine• An attempt to test this hypothesis
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lias "been made by giving a volunteer 1.5g. mepaorine 
iii 3 days and then stopping administration of the 
drug. fwenty four hours after the last dose of 
mepacrime, blood was taken for mepacrine estimation 
and further estimations were made at 24 hour intervals 
in the next 3 days. During this time no mepaorine 
was given so .that absorption was nil and therefore 
constant. If the previous argument is correct 
then the rate of fall in blood mepacrine would be 
expected to be mainly due to degradation of the drug 
within the body. For comparison, the rate of 
degradation in incubated blood was also estimated.
A large sample of blood was taken from the volunteer 
24*hours after the last dose and was divided into 
5 ml. samples that were placed in sterile glass 
stoppered extraction bottles. -Duplicate estimations 
of blood mepaqrine were made soon after the with­
drawal of blood, and then at 24 hour intervals for 
the next 8 days on both circulating and incubated 
Moods. i'he results are shown in fable 34 (Vol.2 p26).
- v  . r
fhe blood mepacrines of the incubated and
circulating "blood. Y/ere almost identical. That • 
is, the rate of degradation in incubated blood 
was the same as the rate of fall in circulating 
"blood mepacrine. Such a close correlation was 
not expected. , To eliminate the possibility of 
a chance observation, similar investigations were 
made on circulating and incubated blood mepacrines 
of another 4 men who were given different doses of 
mepacrine before the test. The results, shown in 
Table 35 (Vol.2 p27) were practically the same as 
those obtained'with the. first volunteers. But in 
addition to the parallelism between the rate of 'fall 
in circulating blood mepacrine and the rate of 
degradation in incubated blood mepacrine, both 
rates were proportional to the amount of mepacrine 
originally present in the blood. ./hen the blood 
levels were high, the rate of fall and the rate of „ 
degradation were more rapid than when the initial 
AleV'©ls- were low. • (Graph. 14 Vol.2 ...P̂6 ) r ' These 
l-^fdings are of fundamental importance in appreciat­
ing: the relationship between blood and tissue
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mepacrine on the one hand; and dose, absorption, •
degradation, and excretion of the drug on the 
other.
If the rate of fall in circulating blood 
mepacrine equals the rate of degradation of. mep­
acrine. in incubated blood then the rate of fall in 
circulating blood mepacrine may be considered to be 
equivalent to the rate of degradation of mepacrine 
in circulating blood. This relationship could 
only hold if rate of degradation in tissues was 
proportional to rate of degradation in circulating 
blood. That is, the rate of degradation in incub­
ated blood equals the rate of degradation in 
circulating blood, and both are proportional to 
the rate of degradation in tissues. But the rates 
o-f degradation in incubated and circulating blood, 
within the limits described, are also proportional 
tcP the7 concentration of mepacrine in the blood, 
life-rate of degradation' in tissues is therefore 
proportional to the concentration of mepacrine in.
t issues 5 that is:-
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rate of'degradation in blood 
rate of degradation in tissues
t
concentration in “blood 
concentration in tissues
a constant
or rate of degradation in blood
concentration in blood
= rate of degradation in tissues
concentration in tissues
= a constant
Two important relationships may be deduced 
from the equations
1. - Blood mepacrine in health is a reliable 
index of tissue mepacrine, as the ratio of the two 
is constant.
2. - Changes in the blood mepacrine, and there­
fore in tissue mepacrine, are attributable to var­
iation in absorption because (a) the blood mepacrine 
level was previously found to depend on the ratio, - 
absorbed mepacrine : degraded mepacrine; and (b) 
because the rate of degradation in blood and tissue 
mepacrine is constant for.a particular blood or 
tissue level.
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The full implications of these findings 
will he discussed later.
When a possible cause for degradation of 
mepacrine within the body is considered, it is ' 
probably significant that tissues, circulating' 
blood, and incubated blood, in addition to having 
proportional'rates'of degradation are also alike 
in having relatively high oxygen tensions and rich 
supplies of oxidative enzymes. This similarity 
is all the more significant when it ‘is appreciated 
that mepacrine in aqueous solution is degraded by 
'bubbling oxygen through it and.by adding oxidising 
agents like hydrogen peroxide. It is therefore 
probable that the first stage in the degradation of 
mepacrine within the body is an oxidative, process.
Mepacrine Partitions. - The investigations so far 
described have dealt with blood mepacrine in health 
and the possible factors that may influence it.
When the chemotherapeutic action of the drug was 
examined, evidence v/as found suggesting that certain 
pathological changes may influence blood mepacrine
profoundly. The rise in blood mepacrine "that 
accompanied fever was attributed to transference 
of mepacrine from tissues to blood. In other 
words the partition of mepacfine between tissues 
and blood was altered by fever. Possible factors 
controlling the partition of mepacrine in a protein: 
water:mepacrine system have been examined because 
investigation of tissuesblood partition in man 
was not practice:!. It was considered that qual­
itative changes in mepacrine partition in this 
simple system probably also apply to the more 
complex mepacrine partitions within the human body.
Denatured egg albumen and mepacrine in 
aqueous solution were employed. The effect of 
time, concentration of the mepacrine solution, pH, 
temperature, and electrolyte concentration on the 
protein mepacrine : v/ater mepacrine partition has 
been examined. The results of the individual 
investigations are not comparable with one another 
because the same preparation of denatured egg 
albumen was not used throughout. This was probably
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of little importance as the object was to define 
qualitative rather than to determine exact quantit­
ative changes. • The results are shown in Graphs 15 
to 17 (Vol.2 p49 to 51).
Staining Time. - The partition o.f. mepacrine 
between protein and water over a period of 160 
minutes has been investigated. At 2-jj minutes 
mepacrine was almost equally divided between 
protein and water, at 20 minutes the protein mep­
acrine: water mepacrine ratio- wa s a s 3 : 1, and at 
160 minutes it was as '6 : 1. (Graph 15 Vol.2 p49).
Concentration of Mepacrine Solution. - Mepacrine 
solutions ranging from 8 to 1000 mg. per litre 
were employed. When the original solution con­
tained 8 mgm. mepacrine per litre of water, the 
protein mepacrine:water, mepacrine ratio was as 1 : 5; 
when it contained 16 mg. mepacrine- per litre, the 
ratio was as 1 : l; when it was 125 mg; per litre, 
the ratio was as o • 1 ; and when it- was 1000 mg. 
per litre, the ratio was as 11 • 1. That is, as 
the mepacrine concentration increased, the protein .
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water mepacrine ratio also increased. (Graph 16 
Vol.2 p50).
Hydrogen Ion Concentration. - The partition of 
mepacrine over a pH range of 2 to 12 was examined, 
from pH.2 to pH.8 the x^otein mepacrine : water 
mepacrine ratio increased from 5 : 1 to 19 : 1 .
Over the range pH.8 to pH.12 the ratio remained 
between 19 : 1 and 18 : 1 . The most pronounced 
change was observed between pH.6 .and pH.8 . (Graph 17 
Vol.2 p5l).
• *
Temperature. - The effects-of temperatures between 
15°C and 70°C^ has been investigated and though the 
protein mepacrine : water mepacrine ratio increased 
from 1.7 1 to 2.8 : 1, the change was insignificant
in comparison with the previous observations (Graph 17 
Vol.2 pol). .
Electrolyte Concentration. - The protein-mepacrine : 
.water mepacrine ratio was as 19 : 1 when thd elect­
rolyte concentration was'0.85g. sodium chloride per . 
100 ml.. It fell to 17.: 1 when the electrolyte 
concentration was 23g. sodium chloride per 100 ml..
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like temperature, electrolyte concentration has 
little influence on the protein-: v/ater partition 
of mepacrine'(Graph 17 Vol.2 p5l).
The staining time, the mepacrine concentration, 
and the pH of the system were found to he important 
in determining the protein : v/ater partition of 
mepacrine. ' They probably also play an important 
part in the pharmacology of the drug. .The complete 
dependence of the partition on the mepacrine con­
centration and the marked change in partition that 
may accompany small pH changes between pH.6 and 8 
are noteworthy. The flattening out of the curve 
pH.8 to 12 may be related to the lower solubility 
of the drug in car alkali solution.
When these findings are translated to the 
administration of mepacrine to man, the staining 
time and mepacrine concentration are represented 
dose and frequency of dosing; the effect of pH 
depends on the pH of tissues and"body fluids. In 
health, pH changes in tissue and blood of men in 
sedentary -occupations vary within n a r r o w  limits so
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that the mepacrine partition between tissues, and 
body fluids v/ould be expected to be fairly constant. 
In disease, greater variation in pH as evidenced by 
changes in the alkali reserve may be found.' Fever 
diminishes the alkali reserve, so that the tissue: 
blood, or tissue :pla,.sma partition of mepacrine may 
be expected to decrease. In other words the blood 
and plasma meyacrines may be expected to rise at 
■the expense of tissue mepacrine. The rise in 
blood mepacrine, that was observed at the time of 
fever without obvious yarasitaemia in volunteers 
experimentally infected with malaria, may therefore 
be due to the diminution in alkali reserve associated 
with fever.
Hydrogen ion concentration may also be partly 
responsible for the striking difference in blood 
mepacrines after oral and parenteral administration 
of the drug. The £icid gastric juice by decreasing 
the partition of mepacrine between the stomach'wall 
and the gastric contents may allow greater amounts 
of the drug to remain in solution within the. stomach,
tne rate of absorption after oral administration 
may therefore be expected to be -slower-than after 
parenteral injection.
Blood, Plasma, and Urinary Mepacrines in Health. - 
In ordinary circumstances a discussion of the 
relations between blood,, plasma, and urinary mep- 
acrines' would be superfluous in view of the previous 
findings. But Shannon*s conclusion regarding the 
respective merits of blood and plasma mepacrine 
in patients sijffering from .malaria, has unfortunate­
ly been extended by others to apply to healthy 
,16individuals. The result has been that blood mep- 
acrine is considered, on the best interpretation, 
to be inferior to plasma mepacrine; and on the 
worst interpretation, to be valueless as a pharma­
cological index. ' - It is significant that this
deduction has not so far been substantiated by 
comparative figures of blood and plasma mepacrine 
in health. Nevertheless, so much confusion has 
been caused by theN opposed views on the respective 
merits of blood and plasma mepacrine in health,
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that aii at tempi; to decide the issue by direct 
comparison has heen'undertaken.
All are agreed that plasma water mepacrine 
and tissue mepacrine are theoretically the best 
indices of pharmacological prop-erties of the drug. 
But since the one is directly proportional to the 
other, either would be acceptable. Unfortunately 
no reliable method exists for festimating plasma 
water mepacrine, and tissue estimation as a routine 
procedure is impracticable. A decision on the 
respective merits of blood mepacrine- and.plasma 
mepacrine,-. as an index of the plasma water mepacrine 
or the .tissue mepacrine, would therefore seem to be 
impossible, for lack of a basis for comparison. But 
as urine in health contains only traces of non- 
diffusible constituents it seems reasonable to 
presume, that urinary mepacrine is closely related 
to plasma water mepacrine. Urinary mepacrine has 
therefore been tentatively employed to compare blood 
and plasma mepacrines of two groups of volunteers 
taking the drug. In one group estimations were
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.made during the period, of dosing; in the other 
group, after dosing had stopped. The single 
extraction method of Brodie and Udenfriend was 
employed for all estimations and fluorescent 
intensities were read on a Coleman Bluorimeter.
The first group of seven volunteers were 
given an initial dose of 0.6g. mexoacrine followed 
after 24 hours by 0.3g. daily for'4 days. Blood 
and rjl&sma mex)a. brines were estimated on the same 
samples of blood taken 4 hours after the first dose 
and at 24 hours after each dose. Urinary mepacrines 
were estimated daily from 24 hour collections. 
.Detailed, results are shown in Table 36 (Vol.2 p28). 
The group mean blood,.plasma, and urinary mepacrines 
showed essentially the same changes during the 
dosing period. (Graph 18 \Tol.2 p52). When the 
relation between blood mepacrine and urine mepacrine 
on the one hand, and between plasma mepacrine and 
urinary merjacrine on the other, was examined by 
plotting the blood-and plasma mepacrines of each 
individual against the urinary mepacrine, the
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variation'in blood:urinary mepacrine ratios was 
less marked than the plasma;urinary mepacrine 
ratios. ■ (Graphs 19 & 20 Vol.2 p53).
The second group of ten volunteers were 
given 5.4g. mepacrine in seven days. Daily blood 
and plasma mepacrines were ma.de on the same samples 
of blood for 27 days starting estimations 24 hours 
after the last dose. Daily urinary mepacrines 
were made on the 3 hours’ urine immediately preceding 
the daily blood sample. Detailed results are shown 
in Table 37 (Vol.2 p29). The group mean blood, 
plasma, and urinary mepacrines from the 2nd to the 
6th day after dosing were practically parallel. 
Thereafter blood and urinary levels continued to 
run parallel, but the plasma mepacrines showed wide 
fluctuations that had no relation to either the 
blood or urinary mepacrine values. (Graph 21 Vol.2 p54). 
The correlation between blood and urinary mepacrines 
was-closer than between the plasma and urinary 
mepacrines (Graphs 22 & 23 Vo?-.2 p55).
In these tv/o investigations a relatively
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wj.de range of Dlood, plasma, and urinary mepaorine 
has been covered and a reasonable correlation -was 
found to exist between blood, plasma, and .urinary 
mepacrines when plasma values were more than 20 ug. 
per litre. But-below this level, plasma mepacrines 
bore no constant relation either to blood mepacrine 
or to urinary mepacrine though blood and urinary 
levels continued to run in parallel. Over-all, 
blood mepacrine was more closely and more consistently 
related to urinary mepacrine than plasma mepacrine.
Bor this reason it was considered to be a better 
pharmacological index in health. Independent 
observations on the degradation of mepacrine have 
resulted in the conclusion that ’blood mepacrine is 
directly proportional to tissue mepacrine. But 
as tissue mepacrine and plasma water mepacrine are 
directly related to one another it may be concluded 
that the basis of comparison employed in this invest­
igation was sound.
The previous generalisation on the value 
of blood mepacrine and pi asms- mepacrine may therefore
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be reversed. Plasma mepacrines in health., 
estimated by single extraction methods are 
almost valueless for reasonably accurate deter­
mination of concentrations less than 20 ug. per 
litre. That is, in the range of concentration 
resulting from suppressive dosds of mepacrine.
This conclusion is amply supported by the erratic 
* -
results of triplicate estimations of plasma mep-
14
acrine that have been reported ' (Cf. *v/ith-triplicate 
estimations of whole blood mepacrines fable 3 7ol.2
p3). But it is not incompatible with Shannon's 
original observation on patients exhibiting wide
variation in leucocyte count.- The important fact
** *
is that physiological variation in leucocyte count
is not sufficient to vitiate results. A somewhat 
similar conclusion was arrived at independently 
by the American workers at Port Knox who compared 
plasma mepacrine and cellular mepacrine of the blood 
calculated from blood estimations and leucocyte 
counts. They found that- the cellular mepacrine of 
healthy soldiers bore a more consistent relationship
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to dose than plasma mepaorine, and on this account 
they advocated reconsideration of the whole prob­
lem of the best index to employ in pharmacological 
investigations
The Pharmacology of Mepacrine: Conclusions. -
Tissue mepacrine may be regarded as the dominant 
factor in the pharmacology of the drug. It 
controls blood mepacrine, the amount of drug 
excreted, and the amount absorbed and degraded.
The specific relations of each of these factors 
to tissue mepacrine will now be considered.
Blood mepacrine in health is directly 
proportional to tissue mepacrine but the actual 
partition between- the two m y  vary with the pH of 
the tissues and blood. In healthy volunteers 
engaged in. sedentary work the partition remains 
fairly constant, but in disease characterised by 
a diminution in the alkali reserve, a decrease in
the tissue : blood partition is expected and the 
blood mepacrine increases at the expense -of the 
tissue mepacrine.
Mepacrine is mainly excreted in the faeces 
and urine. The excretion of the drug has been 
found to be directly proportional to the blood 
level and so to the tissue mepacrine. In other 
words, excretion ox mepacrine is determined by the 
blood and tissue levels of the drug.
Blood and tissue mepacrine. levels are 
determined by the ratio - absorbed, mepacrine : degrad­
ed meiiacrine. When absorbed mepacrine exceeds degrad­
ed mepacrine the blood and tissue mepacrines rise. When 
absorbed mepacrine is less than degraded mepacrine, 
the blood and tissue levels fall. When' absorbed 
mepacrine equals degraded mepacrine, the blood and 
tissue mepacrines are constant. These three phases 
in blood and tissue mepacrine may be identified with 
the build up, the fall away from the peak, and the 
late stable blood mepacrines that have been observed 
after -prolonged administration of hie same doses of
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the drug. The fall awa^' from the peak blood
mepacrine and the assumption of a final stable
bioad-mepacrine level that is about, half the peak
•%
level requires special consideration. The doses
of mepacrine given to prevent malaria are.likely
to be rapidly degraded in the bowel. A little
'more than half the original amount of drug was
recovered from stools 24 hours after the addition
of 50 mg. mepacrine to 50 g. faeces. The longer 
\that mepacrine remains in the bowel, the less will 
be available for absorption owing to degradation 
by intestinal contents. During the build up phase 
absorption is rapid so that degradation within the 
bowel is minimal. When equilibrium between tissues 
and dose is reached, absorption is slower, and so the 
opportunity for degradation within the bowel is 
increased. The nett result is that only a portion 
of the dose is now available for maintenance of a 
tissue : dose equilibrium that was determined in the _ 
first place by the whole dose. The consequence 
is that a new tissue : dose equilibrium has.to.be
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established. This v/ill necessarily be lower than 
the original peak level - hence the fall in blood 
mepacrine to a final level of about half the peak.
Degradation of mepacrine in faeqes, tissues, 
and blood is probably an oxidative process in the 
first place. The rate of degradation in blood and 
faeces has, within limits, been found to be direct­
ly proportional to the amount 'of drug present.
This means that the rate of degradation is constant
for a particular blood, or faecal mepacrine level.
«
But it has also been found that the ratio of the 
rates of degradation in tissues and blood, is equal 
to the ratio of the total mepacrine in tissues and 
blood. Changes in the blood and tissue mepacrine 
levels may therefore be considered to be mainly due’ 
to variation in absorption.
An indication of the relative importance
of the various .factors concerned in maintaining a 
stable blood mepacrine level after prolonged admin­
istration of the drug, and an estimate of the total 
tissue meoscrine maybe obtained-by calculations based
on known data and experimental results. In these 
calculations two assumptions have been made, (l) 
that no mepacrine is degraded in the bowel, and (2) 
that maximal degradation in the bowel is the same 
as the maximal degradation in faeces. In this
way, an estimate of largest and smallest amounts 
of mepacrine in the body has been made. The 
calculations are based on the following data:-
Daily dose of mepacrine = 100 mg.
Average daily faecal mepacrine = 25 mg.
Average d a i ly  urinary mepacrine = 5 mg.
Daily blood mepacrine = 100 ug./litre
Hate of degradation of 100 mg.'
mepacrine in lOOg. faeces = 50 mg./day
Hate of degradation of mepacrine
in blood; initial = 20 ug./day
concentration 100 ug./litre.
I f  the quantity of mepacrine degraded within 
the bowel each day is assumed to be the same as that 
degraded' by faeces in the same time, then the total 
mepacrine lost each day amounts to 80 mg. of the 
daily dose of 100 mg. This includes 50 mg. lost 
by degradation within the bov/el, 25 mg. in the faeces, 
and 5 mg. in the urine. The remaining 20 mg. may
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"be presumed to be necessary to maintain the stable 
blood and tissue mepacrine level, and so are 
equivalent to the total amount .degraded each day. 
But the rate of degradation in blood is about 20 ug. 
per litre per day when the original concentration 
is 100 ug. per litre. fhis is equivalent to a 
total degradation of 100 ug. per day by the blood 
if the blood volume is assumed to be 5 litres. The 
total amount of mepacrine degraded each day was 
.considered to be 20 mg., and the ratio - rate of 
degradation in tissues i rate of degradation in 
blood is a constant, therefore the ratio of the 
daily rates of degradation in tissues and blood is, 
as (20mg. - 100 ug. ) : 100 ug., or as 199 1. But
this ratio is equal to the ratio of the amount of 
mepacrine in tissues and in blood', and the total • 
blood mepacrine is 500 ug. with an assumed blood 
volume of 5 litres. The total tissue mepacrine
during the late stable phase in blood mepacrine. is. 
therefore 199 x 500 ug., that is 99.5 mg.. This 
•figure is based'on the probable maximum degradation
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in the bowel that could occur. If it is n0w 
assumed that no mepacrine is degraded in the bowel 
then only 30 mg. would be lost daily - 25 mg. in 
faeces and o mg. in the urine. The amount degraded 
each day would therefore be equivalent to 70 mg. 
and the ratio, of the rates of degradation in tissues 
and blood would be as 699 : 1, and the total tissue 
merjacrine 349.5 mg. . Ihe true tissue mepacrine 
during the late stable blood mepacrine level probably 
lies between the two extremes, but it is probably 
nearer 99.5 than 349.5 mg.
♦
When mepacrine is given by' intravenous, 
intramuscular, subcutaneous, and rectal injection,
-very high blood mepacrine levels are obtained soon 
after the injection, ihe blood levels after oral 
administration of the same dose are much lower. • Even 
when allowance is made for differences in the circul­
ating system at the different sites of absorption, 
it is considered that the slow rise in blood mep­
acrine and the relatively low levels attained after 
oral administration are due to diminished absorption
~ 9 0 -
frorn ihe pH effect of the acid gastric contents 
and then to degradation of the drug in the intestine.
An initial intramuscular injection of mep­
acrine combined with oral administration of the. 
drug seems io increase absorption of subsequent 
doses given by mouth. ’The blood levels attained
may be very high. flie mechanism of this change
is not understood but it is of interest that a
similar finding has been reported with another
18antimalarial drug. Howie and. Murray-Lyon found 
that 110 quinine appeared in the urine of certain 
patients taking large doses of the drug by mouth. 
After intravenous injection of quinine, large 
amounts of the drug appeared in the urine of these 
patients, and most important, large amounts continued 
to appear in the urine when subsequent doses of the 
drug were given by mouth.
PART 3
ht£EA.CRIhb TOXICITY ' v
Headache, vomiting, diarrhoea, abdominal 
*
. colic, muscle cramps, epilepsy, and psychosis 
have been attributed to the administration of 
large doses'of mepacrine to patients with malaria. 
Unfortunately it is not possible to decide to what 
extent mepacrine, and to what extent the disease, was 
responsible. Undesirable effects that were most 
probably due to mepacrine have been encountered 
in a few healthy volunteers who were taking the drug. 
The relation of these toxic manifestations to blood 
and urinary mepacrine has been examined by comparing 
the blood and urinary values of volunteers who devel­
oped undesirable effects, with the values of symptom- 
free volunteers who took the same doses of the drug 
at the same times. If a definite correlation could
be established between toxic effects and blood and ✓
urinary mepacrine, then it was hoped to define the 
minimum blood and urinary levels at which toxic effects
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were encount ered.
In addition to acute toxic effects 
encountered during the administration of large 
doses of mepacrine, the possibility of cumulative 
chronic toxic effects resulting from prolonged 
administration of small doses of mepacrine had also 
to be borne in mind, because soldiers operating in 
malarious areas may have to take the drug continuous­
ly for 1 to 2 years, or perhaps even longer. Both 
aspects.of mepacrine toxicity have been studied and 
they will be dealt with separately.
Acute Toxicity. - The acute toxic symptoms that
have arisen are conveniently divided into three 
classes:-
(1) Mild symptoms such as headache, nausea, 
epigastric-discomfort, and, minor visual 
disturbances that were entirely subject­
ive and were not sufficiently severe to 
interfere with ordinary duties.
(2) Alimentary symptoms like vomiting, colic, 
and diarrhoea that were temporarily 
incapacitating.
(3 ) Severe systemic effects characterised by 
marked lassitude and depression and 
sometimes accompanied by neuralgic pains 
that were wholly incapacitating.
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Mild Symptoms. - Headache, nausea, epigastric 
discomfort, and minor visual disturbances were 
most frequently encountered. ' They occurred 
after administration of large doses of mepacrine 
(0.5g.) and also after small doses (O.lg.). But 
when small doses continued to be taken, symptoms 
disappeared and did not recur. Because of the 
mild nature of the symptoms and their complete 
dependence on the subjective sensations of the 
individual, it was not possible to classify them 
satisfactorily. Ho further investigation was 
therefore possible.
A1imentary Symptoms. - The effect of fluid intake 
on the appearance of toxic effec'ts from mepacrine 
has been'investigated. Two groups of volunteers, 
each containing 6 healthy men, were given th’e same 
doses of mepacrine at the same times. The fluid 
intake of one group was .restricted for 3 days 
before, and on the day of taking mepacrine.. The 
fluid intake of the other group was liberal. Both 
groups were confined to bed in different wards on
the day mepacrine was given. The doses employed 
were as -follows
Initial dose 0.2g. mepacrine
After 5 hours 0.3g. mepacrine
After 10 hours 0.4g. mepacrine
After 15 hours • O.og. mepacrine-
Total dose l»4g. mepacrine
The urinary output of the restricted fluid intake 
group ranged from 240 to 900 ml. on the day of 
test; that of the other group ranged from 1,700 
to 2,400 ml. on the same day (Table 38 Vol.2 p30).
Hive of the six men taking a restricted 
fluid intake had abdominal colic and loose watery 
stools. Movement of the bowels relieved the colic. 
These manifestations did not appear in the men 
taking a liberal fluid intake.
Blood samples for mepacrine estimations 
were, taken at i hour, f hour, 2-j- hours, 5 hours,
10 hours, 14-jjr hours, and 23-J- hours after the 
initial dose. The total mepacrine excreted in 
the urine in the 24 hours after the initial dose 
was also- estimated. The results are shown in
Tables 39 a?id 40 (Vol.2 p31 & 32). The group 
mean blood mepacrines of the two groups did not . 
differ markedly. Hor practical purposes they 
may be regarded as the same. The urinary mepacrines 
on the other hand .were much lower in the restricted 
fluid intake group than in the liberal fluid intake 
group. That is, colic and diarrhoea we re not 
related to blood mepacrine but appeared to be 
associated with low urinary mepacrines. The only 
explanation that can be offered for the similarity 
in blood mepacrines of the two groups and the 
disparity in urinary mepacrines is that the tissue: 
blood partition of the drug was lower in the res­
tricted fluid intake group than in the liberal 
fluid intake group. In consequence it seems 
reasonable to suppose that less mepacrine was 
absorbed by the restricted fluid intake group and 
therefore more was left in the alimentary tract. 
Diarrhoea and colic may therefore be due to 
direct action of mepacrine on the bowel. The 
•hinge on which this argument is based, namely,
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that -the tissue:blood partition of the drug was 
different in the two groups, is supported by the 
fact that dehydration is usually associated with 
a diminished alkali reserve; and a small change 
in pH has, already been found to alter the drug 
partition in the manner described.
Severe Systemic Effects. - Six medical officers 
took a single daily dose of 0.5g. mepacrine for 
5 days whilst carrying out sedentary duties, 
i'wo developed severe systemic toxic manifestations, 
the other four were unaffected.
Blood mepacrines of the six men were 
estimated immediately before and 24 hours after 
the fifth and last dose. Then estimations'were 
made every other day for the next week. Twenty 
four hour urinary mepacrines were estimated during 
the a days of dosing, and during the 6 days after 
dosing. Details of the toxic effects were as 
follows:-
Lieut.I. had severe headache a few hours after the^ 
first two doses of mepacrine. The headache lasted 
11 hours on the first day and o hours on the second
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day. Immediately after the 3rd, 4th, and 5th doses 
ne v/6.s perxec bly fit and had no complaints, but 18 
hours after the 5th dose at 3 a.m. on the 6th day, 
he wakened with pain in both loins. He was thirsty 
ha,a pain in his tongue, his mouth was dry,; and he * 
was sweating profusely.' He quenched his thirst but 
could not sleep as he felt very excited. At 9 a.m. 
on the same day he was much improved and reported 
for examination when he complained of excessive 
salivation, a bitter taste in his mouth, and thirst. 
His urine was albumen-free and contained no macro­
scopic blood. He loomed tired and felt out of 
sorts bub carried out his duties until the afternoon 
of the 7th day when he had to. return to bed.' He 
was fairly comfortable until evening when pain behind 
the eyes, pain in the maxilla, and pain in the 
lumbo-sacral region radiating down the left leg 
developed. His pulse rate was 120 per minute and, 
his temperature was 101°P.. The muscles of both
thighs felt tight and spasmodic twitching of 
bundles of' muscle fibres was observed. He was 
given two Codeine Phos.Co. tablets and slept fairly 
well-. On the morning of the 8th day he noticed 
an erythematious rash on the chest and flexor aspects 
of the arms. fie left weak, but was comfortable in 
bed. . On the morning of the 9th day he was allowed 
up and walked with a perceptible limp. The rash 
was still present and small erythema,tious patches 
were observed on the chest and .on the .flexor aspects 
of the arms (illustration Vol.2 poS). On the 10th 
day the rash was fading and had disappeared on the 
11th day. On the 12th day he was able to resume 
duties.
Capt.Q-. - During the first 3 days of mepacrine 
dosing this officer complained of ej)igastric 
discomfort, nausea, thirst, headache,^and mental^ 
confusion, but was able to continue with his duties.
He was perfectly fit on the 4th and bth -days but on 
the forenoon of the 6th day he- felt very v/eak, 
depressed, generally out of sorts, and had to retire 
to bed. Symptoms persisted on the 7th day, but on 
the 8th day^he was fit enough to resume his duties.
ine blood, mepacrines of the two volunteers 
who had severe .'reactions after mepacrine administ­
ration, and the values of the other four men who 
were unaffected, are shown in Table 41 (Vol.2 p33).
The urinary mepacrines are given in Table 42 (Vol.2 p34) 
The blood mepacrine of the individuals with incapacit­
ating toxic effects were higher than the values of 
the others at the time symptoms were present. The 
urinary mepacrines were no different from those of 
the symptom-free volunteers. Severe systemic 
toxic effects would therefore seem to be associated 
with a high post absorptive blood mepacrine. A 
level of about 800 ug. per litre 24 hours after 
the dose was not associated with symptoms but a 
level of more than 1,000 ug. per litre was. Severe 
toxic manifestations would therefore appear to be 
associated with a high tissue concentration of the 
drug.
Investigations of acute mepacrine . toxicity 
are necessarily incomplete because toxic effects 
'develop accidentally and therefore few volunteers
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wexe available xor study. But the results obtained 
. suggest that alimentary symptoms by themselves, are 
due to looal, action of mepacrine on the bowel; and 
severe systemic effects associated with a high blood 
mepacrine are due to a high tissue concentration of 
the drug. From the nature of the symptoms, the 
^nervous system'would appear to bear the brunt of 
the toxic action. i’he maximum safe post absorptive, 
blood mepacrine is tentatively defined at 800 ug. 
per litre.
Dehydration favours the occurrence of 
alimentary symptoms. A liberal fluid intake with
each dose of mepacrine will therefore prevent or at 
least minimise vomiting, colic, and diarrhoea.
*
Chronic Toxicity. - Experiment's on laboratory
animals have shown that large doses of mepacrine
19,20
cause' necrosis of the .liver.. Isolated reports
of liver necrosis in human subjects taking mep­
acrine have neither x^noved nor disproved that
Published in The Lancet _2, 107, 194a. in 
collaboration with Lt. Col. W*R.M.Drew.
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mepctCline, was responsible. The yellow staining 
of che skin of white men that' results from taking 
mepacrine may have lent supx>ort to the belief that 
mepacrine was a liver poison because of the early 
difficulty in distinguishing it from jaundice.
At the time this problem was being discussed 
British troops who had taken mepacrine as a malarial 
suppressive for periods ranging from 4' to 18 months, 
were returning home from West Africa. It was 
decided to examine a number of them to discover 
whether or not liver damage or any other significant 
disability had developed during their stay in the 
tropics. In these men positive findings would 
not necessarily implicate mepacrine, but negative 
findings would provide good evidence that mepacrine, 
taken in suppressive doses for jjrolonged periods, 
did not' cause serious ill effects.
Investigations. — One hundred and tv/o men, still 
taking Q.lg. mepacrine daily were available for 
study. Investigations were carried out on the 
following lines:-
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'Careful inquiry was made about the' 
.regularity with which mepacrine had been taken, 
about possible symptoms from taking the drug,' and 
abo u b a t U a cks of malaria and other diseases during ' 
the period_ of service in 'test Africa.
Complete clinical examination was undertaken
Particular attention was paid to the size of liver
and spleen. Liver function was assessed by the
gohippuric acid synthesis test. If the test was 
abnormal or if there was any other reason to suspect 
liver involvement - such as hepatic or splenic 
enlargement - a further series of liver function 
tests was carried out. fhese included estimations
of serum bilirubin, plasma protein, and serum phos-
gl 22phatase, and the sucrose tolerance test.
Histological examination of the liver was
' ' 23 . - . -•also carried out by liver puncture biopsy on
volunteers with hepatic or splenic enlargement or
an abnormal hippuric.acid synthesis test.
Other investigations were:- blood-counts, .
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including differential leucocyte count and an 
examination of thick and thin films for malaria 
parasites; faecal cultures for pathogenic bacteria; 
microscopic examination of stools for parasitic 
cysts, eggs, and. worms, ■ examination of the urine 
for abnormal constituents; and assessment of renal 
function hy the urea-clearance test. i'he results 
are most conveniently considered' under these headings.
Mepacrine Administration. - The 102 soldiers
examined, had been in West Africa for periods 
3-ranginf from 8 to 36 months. All had been under 
orders to take mepacrine during the last 4 - 1 8  
months of their stay. Thirteen had been ordered 
0 .2g . twice w.eekly fox1 an initial period of 1 — 3 
months; after this period all were ordered O.lg. 
daily on six days of each week. ..The taking of the 
drug was supervised with a degree of thoroughness 
that varied considerably in different units.
five men /had complained ' of vomiting during 
the first week on mepacrine; seven others reported 
insomnia and nightmares after the drug nad. been
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taken for several weeks; and two stated that 
these symptoms were especially noticeable when 
^bls iis ^ei c tuxen wiuhout water. These symptoms 
were never bad enough to interfere with duty or 
compel the men to stop taking^the drug..
Incidence of Malaria and Other Diseases. - All the 
men had toeen exposed to malarial infection from 2 
to 31 months before mepacrine was taken. During • 
this time quinine was taken in a daily dose of 
grains 5 to reduce the incidence of malaria; on . 
quinine suppression 70 men had 250 attacks of 
malaria and one had blackwater fever. for a 
comparable 'period on suppressive mepacrine, 40 men 
had 79 attacks of malaria and none had blackwater 
fever.
Next to malaria, dysentery was the commonest 
cause of illness. Sixteen men had dysentery - 
■eight bhcillary, five amoebic, and three of unspec-. 
ified origin. The only other important diseases 
were jaundice and syphilis. four of the 102 men 
had jaundice; attributed in two to infective
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hepatitis, 111 one to yellow fever inoculation, '
ĉ nd in Liie fourth to arsenical treatment for 
syphilis.
— l a dings. — Yellow staining of the skin 
from mepacrine w a s  visible in all the men. The 
intensify of staining varied in different individuals 
being well marked in 26, moderate in 65, and slight 
in 11. Colouration was most marked on the exposed 
parts of the body, and this may have been due to 
mepacrine deposition plus natural tanning. ' There 
were'no skin lesions. Two men who showed staining 
of the conjunctivae had serum bilirubin values of 
0.4mg. and Q.omg. per 100 c.em. blood. The edge 
of the liver was about two fingers-breadth below 
the costal margin on full inspiration in 9 men,* 
the spleen was palpable in thirteen.
Liver function Tests. - The hippuric acid synthesis 
test was abnormal in 9 of the 102 men* The abnormal­
ity was of moderate degree in 7 and marked in two.
The other liver function tests carried out on these 
9 men on the following day were all within noim&l
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limits. The hippuric acid synthesis test was 
repeated after four months on 8 of the 9 men 
whose first test had shown abnormal values.
During these four months they took no mepacrine. 
On this -second test normal results v/ere recorded 
in 7 men, and an abnormal value persisted in only 
one .
Liver Puncture Biopsy. - Ten men, who had taken
mepacrine regularly for 6 to 17 months, v/ere*
transferred to the British Post-Graduate Medical *
School for liver puncture to be performed by
D r .J.MeMichael and Dr.S.P.V.Sherlock. Of these,
*
seven had slight hepatic or splenic enlargement 
or an abnormal hippuric acid synthesis test. 
Clinical and biochemical findings v/ere normal in 
the other three and they served as controls. No 
ill effects, resulted from the liver puncture.
Professor J.H.Dible, who kindly examined 
the sections, reported as followss-
"The livers on the whole show no 
departure from normal, with the exception 
of some haemozoin pigment in the reticulo­
endothelial 'cells, .and slight excess of
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iron in about one-half of the cases. The 
former,- I imagine, is only to be expected 
in men who have suffered from malaria in 
file not very disfanf past. The laffer 
may he associated' with anaemia. Apart from 
these observations, the.livers appear healthy 
or show only slight variations such as one 
would 'consider to be within physiological 
limits."
Blood, Stool, end Urine Examinations. - The red­
cell count ranged from, 3.6 to 3.5 millions per 
c.mm.. The leucocyte count varied from 4,000 to 
15,000 per c.mm. and averaged 6,000. The' 
differential leucocyte count was within normal 
limits in 100 men. Two men showed an eosinophilis, 
- one of 25>q and one of 11$. [Parasites of benign
tertian malaria (Plasmodium vivax) were found in,
?■
only one thick blood film.
- . Cysts of Entamoeba histolytica were.' found 
in the stools of three men. ho pathogenic 
bacterici v/ere isolated on culture from the stools. 
No abnormal constituents were found in the urine,
' except a trace of albumen on one occasion. * The 
urea—clearance tests v/ere all within normal limits.
Conclusions. - falciparum malaria was by far the
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most frequent disease encountered in West Africa. 
Eighty-four men had 329 attacks in 3 - 3 6  months. 
Eighteen men escaped a recognised attack of the 
disease.
At first sight this 'may appear to be a 
high incidence of malaria, but it must.be remembered 
that in a hyperendemic area like West Africa, the 
incidence of malaria would.probably be at least 
100$ per month if no anti-malarial precautions 
were taken. It should also be realised that the 
malarial incidence varied enormously with the 
quality of unit anti-malarial discipline, including 
the administration of suppressive drugs.
Blight enlargement of the liver and spleen
has also been found in Australian soldiers taking
suppressive mepacrine after experimental infection
16with falciparum malaria. , •
The finding of a moderately abnormal hippuric 
acid synthesis test in seven men, and a markedly
abnormal test in two men is not considered to have
much, significance, since other liver function tests
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and -fche histological appearance of the liver 
v/ere within physiological limits. At most, 
the defective hippuric acid tests, might indicate 
a temporary derangement in liver function, as 
normal values v/ere found in all but one man when 
the test was repeated later. Moreover, this 
upset cannot be attributed to mepacrine; for 
other factors, such as malarih were involved.
Other: findings worthy of note were: a
lowered red-cell count in an appreciable number 
of men, an unexplained eosinophilia in two men, 
and cysts of E.histolytica in the stools of three- 
men. In 30 men the red-cell count ranged from 
3.6 to 4.5 millions per c.mm. blood; but this 
slight anemia, which is probably a legacy of 
malaria, rapidly disappears after a therapeutic 
course of mepacrine.
Residence of from 8 to 36 months in West. 
Africa need not of itself .cause serious impairment to 
health. The greatest hazard is falciparum 
malaria, and its most'serious effects may be
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effectively prevented by strict observance of 
all anti-malarial precautions including the 
regular taking of mepacrine. In a proportion 
of men exposed for a long time to malarial 
infection slight hepatic and splenic enlargement 
may result while mepacrine is being taken, 
liver function tests and histological examination 
indicate that no change in liver function or 
structure results from taking the drug. In short, 
there is no evidence that mepacrine in suppressive 
doses taken for 4 - IS months has any cumulative 
toxic action on the liver, kidney, or blood-forming 
tissues. On the contrary, there is good reason 
to claim that the drug can eliminate severe and 
fatal forms of malignant tertian malaria, as well 
as serious complications like blackwater fever and 
much chronic ill health resulting from frequent 
attacks of malaria.
Since this.investigation, a skin disease ' 
resembling lichen planus has been reported in a 
small proportion of individuals who have taken
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mepacrine for prolonged periods; but whether
the disease is incidental or related to .the 
taking of mepacrine is still uncertain.
- Ill -
PARI' 4 ■
THE PREVENTION AND TREATMENT OP MALARIA 
.VI TIi MEPACRINE
Malaria Prevention. - The prevention of malaria
with mepacrine has been found to be related to the 
amount of the drug in the blood. The minimum 
effective post absorptive level has been defined as 
100 ug. per’ litre. When the blood mepacrine falls 
below this level, malarial fever may be expected in 
individuals infected with the disease. Whether 
fever is self-limiting or whether it develops into 
a frank attack of malaria depends on the tissue 
reserves of mepacrine and on the magnitude of the 
rise in blood mepacrine that accompanies the 
nacidosis”' of fever.
The blood mepacrines after prolonged 
administration of ^.aily doses of O.lg., and- weekly 
doses of G.og. of the drug preceded by a loading 
dose, have been defined. With both regimes stable
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group mean blood mepacrines of about 100 ug.’ per 
litre we re reached after 40 to 50 days, so that 
at any time after the sixth week about half the. 
number of volunteers could be expect-ed to have, 
blood mepacrines below 100 ug. per litre. If 
these men were being continuously infected with 
sporozoites in a hyperendemic malarious area they 
would be expected to develop a short term, self- 
limiting fever, that would not usually be associated 
with parasitaemia. It is difficult to decide the 
practical importance of this fever because of lack 
of information on’ the natural rate of infection - 
and because of the absence of reliable figures on 
the incidence of short term "Pyrexias of Unknown 
Origin" in the field. But in 25 volunteers taking
O.lg. mepacrine daily, who were experimentally 
infected with sporozoites of falciparum malaria,
12 volunteers developed fever within 14 days of 
infection. The'fever was of 1 day’s duration in 
8 men, 2 days’ duration irt 3 men, and of. 3 days’ 
duration in the remaining volunteers. That is,
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in 14 days about half the volunteers v/ere fevered 
for an average period of about 1-J- days. If it 
is assumed that tne rate of infection in a hyper— 
endemic area is 10GC;S per month, then with 0 .lg. 
•mepacrine daily, about half the number of men 
would have fever for 1-y days every month. Short 
term pyrexia therefore deserves careful attention 
because it will tend to undermine' health and reduce
physical fitness rather than cause an acute disaster.
%
It will be difficult if not" impossible to recognise 
its essential connection with mala ria in the field, 
because other causes of P.TJ.Q. have to be considered. 
But its occurrence in such a large proportion of 
volunteers infected with malaria in.this country . 
is most significant. The fever occurred regularly 
at about the same time after infection in different 
groups of volunteers who were taking mepacrine and 
other antimalarial drugs. Subinoculation of 
another individual, with blood' from a volunteer . 
with fever but no demonstrable parasitaemia, resulted 
in the successful transmission of the disease.
Subsidence ox' fever coincided with a spoilt-
v
•aneous rise- in blood mepacrine. These findings, 
together with the fact that fever could not "be. 
attributed to any other cause, make it almost
/
certain that it is a malarial manifestation.
Many P.O. Os have "been, reported from hyper end emio 
malarious areas and it is likely that the majority 
are malarial in origin.
The real incidence of short term P.U.Q. 
in hyperendemic malarious areas has not.been 
determined because statistics have mainly been 
prepared from the returns of hospital admissions, 
and it is the usual practice to allow 48 hours •
.to elapse before an admission is recorded. If 
the patient is fit within this i i/ i m e, no admission 
is registered, and since it may take several 
days to reach .hospital many of the short term 
malarial P.U.Os will have cured themselves and 
will not have been reported. Por these reasons 
a careful check of the real incidence of P.U.O.
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in a hyperendemio malarious area is advocated 
so i/hat its eiiect 011 manpower may be properly 
assessed* Moreover, as there is evidence to 
suggest that a higher group mean blood mepacrine 
may prevent short term lever, trials with larger 
doses of mepacrine are also recommended. In 
this connection it is interesting to*note tint 
daily doses of G.hg. mepacrine have been used by 
small units in Burma without toxic effects, and 
with success in the prevention of malaria.
It should be made perfectly clear that 
assessment of the value of O.lg. mepacrine daily 
has been made under very stringent conditions because 
the issues i.o be decided were . of vital importance 
ana did not permit a more elastic interpretation.
It may be argued that the employment of other 
protective measures like nets, repellants, and 
insecticides, may so reduce the rate of infection 
that short term fever will be of little importance. 
This may be true under static conditions and during 
quiet periods when these measures may be properly
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carried out, but it lias not been the usual 
experience under conditions ox stress. Both 
in Burma and Sicily when active fighting was in 
progress malaria rates increased.' The other 
protective measures were largely discarded by 
fighting soldiers because they v/ere alleged to 
interfere with military efficiency. In an 
emergency reliance has to be placed almost entirely 
on mepacrine. -It is the most valuable drug we 
possess at present for the prevention of malaria. 
Nothing that has been said is intended to detract 
•from this statement. It has effectively checked 
falciparum malaria, a disease that if left uncon­
trolled would have made sustained military operations 
in hyperendemic malarious areas impossible; it has 
undoubtedly prevented many deaths from malaria, and 
reduced chronic disability from serious complications 
of the disease. But, because it may be used to- 
even greater advantage the view that O.lg. mepacrine 
daily will prevent malaria is considered to be 
misleading. It is for practical purposes true, 
if para,sites have to be demonstrated in a patient’s
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blood before malaria is diagnosed. Unfortunately 
failure to demonstrate parasites does not alter 
the fact that an individual with fever is not 
fit. furthermore, the statement has been taken 
at its face value and the onset of malaria has 
been■considered to be evidence of a breaph in 
mepacrine discipline, and therefore, a punishable 
offence. It is difficult on the evidence available, 
even on grounds of expediency, to justify this 
procedure. An open mind and further work are 
still necessary before a final decision on the 
ultimate value of mepacrine as a preventive. of . 
malaria and its manifestations can be made. But 
the indications are that if a group* mean blood 
level of about 200 ug. per litre can be maintained, 
short term fever as well as frank malaria may be 
prevented.
Treatment- of an Attack of Malaria. - A post 
absorptive blood mepacrine of 100 ug. per litre 
has*been found to prevent the occurrence of 
falciparum malaria after sporozoite infection.
- ii a -
lower levels are not effective. It is also 
Imowii that a more rapid clinical response is 
obtained with large doses of mepacrine than with 
small doses. The upper safe post absorptive 
blood mepacrine has been'tentatively defined 
as 800 ug. per litre. • The aim of treatment 
of malaria with mepacrine is therefore* to raise 
the blood mepacrine to a post absorptive level 
of more than 100 ug. per litre, and as near to 
800 ug. per litre, as quickly as possible. This 
may be effected by parenteral or by oral admin­
istration of the drug. But as very high levels 
may be attained with combined parent eral and 
oral treatmentthe combination is not recom­
mended for general use until further observations 
have been made. Only in dangerously ill patients 
should parenteral treatment be given. In these 
circumstances-an initial dose of 0.2g. mepacrine
followed by three O.lg. doses may.be given by
\intramuscular injectio.n in the first 24 hours. 
Subcutaneous injection should be avoided. No
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ill effects resulted after injection of the 
*drug'by this route into healthy volunteers, hut 
when Q,2g. in 10 ml. distilled water was given 
by subcutaneous injection to a patient with 
malaria,, a large ulcer developed at the site * 
of injection that took fully 6 weeks to heal 
(Photograph Vc£L2 p57).
The maximal total dose that may be given 
by mouth to a healthy adult male without the 
risk of incurring serious toxic effects is 
considered to be 3.0g. mepacrine in 5 to 7 days. 
The following dosage regime is recommended for 
trial:- .a maximum total of l.Og. in the first 
24 hours; divided into 3 doses of G.3g., 0#3g, 
and 0.4g. at six-hour intervals; followed by
0.5g. daily for the next four days, either as 
single doses or preferably divided into twice 
daily doses of 0.2g. in the morning and- 0.3g. in 
the evening. & liberal fluid intake should be 
prescribed and at least half a pint of water 
should be given with each dose if the alimentary
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symptoms due to mepacrine are to be avoided.
These symptoms will tend to be aggravated by 
the dehydration-associated with malaria.
Before concluding, it may be useful to 
discuss briefly the methods of investigation 
employed in this work to decide whether they 
have a more general application in testing other 
drugs. The first departure from the usual 
practice was to undertake concurrent investigations 
on chemotherapy, pharmacology, and toxicity. The 
second, was to employ concentration of the drug at 
its probable site of action instead of dose as a- 
reference index for these investigations. As a 
result, it may fairly be claimed that the value of 
mepacrine as an anti malarial agent has been defined' 
in a shorter time, and with more precision than 
v/ould have been possible by the older empirical 
method. Advances in biochemical technique, and 
the introduction of sensitive fluorimeters and 
colorimeters have made it possible to estimate 
ranges of concentration of drugs in biological
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fluids that v/ere hitherto impossible. This has 
enabled the greatest possible benefit to be 
derived from a combined study of chemotherapy, 
pharmacology, and toxicity.
Before the therapeutic value of a drug 
is known, three properties have to be defined
1. - The minimum concentration of the drug 
at the site of action that will give a maximum 
therapeutic response.
2. - The concentration of the drug at 
its site of action in relation to dose.
3. - The maximum concentration of the drug 
at the site of action that is free from undesirable 
toxic effects.
It is considered that the same technique 
as has been employed for mepacrine may also be 
applied to almost ali diseases in which drugs have 
a beneficial or curative action.
The advantages of this approach over the 
older method of assessing the value of a drug are
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considerable. In addition to being a quicker, 
more precise, -and more logical approach, it- is 
less likely , to be associated, with toxic effects 
from overdosing, or protracted illness from under­
dosing — the usual accompaniments of new drugs soon 
after their introduction. These effects may be 
avoided because treatment need not start and finish 
with the administration of drugs, it may be con­
trolled throughout the course of the disease by 
appropriate estimation of drug concentration in 
biological fluids. These are the obvious advant-' 
ages, but there are others that.ard probably even 
more important. In the work on inepacrime; observat­
ions on the chemotherapeutic action of the drug; on 
the partition of the drug between blood and tissues; 
on the absorption, degradation, excretion, and 
toxicity of the drug: have all been leading to
the same end, namely, the identification of a. 
particular biological reaction with the physical 
and chemical properties of mepacrine. ' Further 
Investigation aleng these lines is still necessary,
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but. 11} is reasonable "to hope that "therapeutic, 
pharmacological, and toxic properties of drugs 
may eventually be associated with particular 
physical and chemical properties. When this 
has been achieved it may be possible to introduce 
new remedies for the treatment of disease that 
are not, as at present, wholly dependent on more 
or less fortuitous discoveries in the general 
field of biology.
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1. - Prevention of falciparum malaria in volunt­
eers experimentally infected with sporozoites has 
"been found to depend on the concentration of 
mepacrine in the "blood. When the blood mepacrine 
is 100 ug. per litre or more, malaria does not
_ appear. But, when the blood mepacrine is less 
than 1QG ug. per litre, a fever develops that is 
almost certainly malarial in origin, though par­
asites are not usually found in the blood. Whether 
this fever is self-limiting, or whether it develops 
into a frank attack of malaria, depends on whether
enough mepacrine is transferred from tissues to
w •-the blood to raise the blood mepacrine to a 
parasiticidal level. fhe transference of mepacrine 
from tissues to the blood is considered to be due 
to a diminution in the 'tissue : blood partition
-Of the drug resulting from the change in pH. of
/
■ tissues and blood that accompanies fever. -
2. - file dye properties of mepacrine are most
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important in determining the distribution of the 
drug in the body. fhe drug tends to concentrate 
in tissues rather than in internal body fluids., 
lor this reason tissue mepacrine is the dominant 
pharmacological factor. It is largely responsible 
for the persistence of the drug in the body long 
after dosing has been- stopped. Blood mepacrine 
is directly proportional to tissue mepacrine, and 
the partition of the drug between the two is 
determined by the pH of tissues and blood. In 
healthy men engaged in sedentary occupations, the 
tissue : blood partition is practically constant.
In disease associated v/ith diminution in pH of 
tissues and blood, the partition may be markedly 
diminished, v/ith the result that blood mepacrine 
increases at the expense of tissue mepacrine.
fhe blood- and. tissue-mepaarine levels 
of healthy individuals depend mainly on dose, 
lor each dose, an equilibrium betv/een dose and 
blood- and tissue-mepacrine, is eventually reached.
fhe greater the dose, the higher the blood- and
Absorption of mepacrine is inversely 
proportional to the blood- and tissue-levels p.f 
the drug-* ihat is, wuen blood- and tissue—levels 
are low, maximal aoaorption takes place; when 
'iOjoiidr— and tissue—levels are in equilibrium with 
dose, absorption is minimal and is uetermined by 
the amount oi drug degraded in the tissues.
Jleg3?ada.tion of mepacrine which occurs in 
-tissues, blpodj-and alimentary tract is probably 
an oxidative pro case in the first place. .Evidence 
has been found suggesting that the rate of degrad­
ation in blood is proportional to the rate of 
degradation in tissues, and that both are proportional 
to the respective concentration in blood ;̂nd tissues. 
Degradation by alimentary contents is considered to 
be mainly responsible for the .fall .in blood mepacrine 
from the initial peak, to the late stable level that 
has been observed after prolonged administi?a^fci#n of 
the drug.
Itepacrine is mainly excreted :in urine and
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faeces, and the total excretion of the drug'is 
determined by the blood- and tissue-mepacrine 
levels. When these are high, greater amounts 
are excreted than when they are low.
After tablets by mouth, the blcrod mepacrine 
is much lower than after parenteral 'or rectal 
injection of the same dose. fhe difference is 
due, partly to the time required for solutipn of •  ̂
the tablets, partly to the pH effect of the gastric 
contents, and partly to diminished absorption result­
ing fro up degradation of mepacrine in the bowel. 
Combined parenteral and Oral administration may
result in very high blood-mepacrine levels. Barent- 
%eral injection seems, in a way that is not understood, 
to*increase subsequent absorption from the bowel.
3. - foxic effects from mepacrine may arise soon 
after administration of the drug. ‘ fhey may be 
mild, temporarily incapacitating, or wholly incapacit­
ating. Mild symptoms; line headache, nausea, 
epigastric discomfort, and minor visual disturbances - 
are most frequent, and occur'with large and small
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doses of the drug. They pass off if administration 
of small doses is continued, temporary incapacit­
ating symptoms - such as vomiting, colic, and 
diarrhoea are considered to he mainly due to local 
action of mepacrine on the bowel, They may he 
.avoided, or at.least minimised, by ensuring a liberal 
fluid intake. Wholly incapacitating effects - 
characterised by lassitude and depression, and 
sometimes by localised neurological symptoms - are 
associated v/ith high blood- and tissue-mepacrines, 
and arise only when large doses of the drug are 
given. The nervous system seems to bear the brunt 
of the initial toxic action.
Prolonged administration of mepacrine in 
doses of O.lg. daily does not appear to cause 
damage to the liver, kidneys, or blood-forming 
tissues. A skin lesion, resembling-lichen planus, 
has been reported after prolonged administration 
of the drug, but its specific connection with 
mepacrine is still uncertain.
4. — loses of O.lg. mepacrine daily will prevent
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frank malaria in the majority of individuals
taking the drug. But, if infection is heavy,
a considerable proportion of those infected may .*
be expected to develop a short-term, self-limiting 
fever that is essentially malarial in origin. 
Available evidence suggests that this fever may 
also be prevented by maintaining a higher, stable 
blood-mepacrine level. Bor this reason a careful 
assessment of the incidence of "Pyrexia of Unknown 
•Origin" in hyperendemic regions is advocated, as 
well'as preliminary.trials with larger doses of the 
drug.
5. - The aim of the treatment of malaria v/ith 
mepacrine is to raise the blood mepaerine above 
100 ug. per litre, and near to 800 ug. per litre,, 
as quickly as possible. A dosage regime that .will 
give'maximal safe blood mepacrines has been put 
forward for trial. Treatment by parenteral inject­
ion of mepacrine should, at present,- be reserved for 
seriously ill patients. ■
6. - Advantage has been taken of improvements
- To 0 -
in biochemical, -technique to investigate the 
chemotherapeutic, pharmacological, and toxic 
action of mepacrine concurrently. 'The concent­
ration of the drug in the "blood has "been employed 
as the reference index instead of dose. i'he work . 
so fa.r completed, and investigations in progress, 
suggest that 'mepacrine acts directly on malarial 
parasites. This action may depend on blocking 
oxidative enzyme systems within the parasite.
Toxic action in man may also depend on the same 
mechanism.
fhe advantages of the methods employed 
in this work over the older methods of assessing 
the value of a drug have been discussed. The 
same technique may be usefully employed to assess 
the therapeutic value of almost any drug that has 
a curative action in disease.
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No. of Volunteers 
Month of developing:-
Infection Malaria Pever No Reactions
1 25 Sept.- Oct'.1943 1 11 13
2 *7 Nov.- Dec.1943 0 2 5
3 . 6 Feb.- March.1944 3 2 1
4 1.2 . ■ June 1944 6 4 2
5 4 Sept.1944 2 1 ■ 1
Groups 1, 2, 3, and 4 were infected by mosquito bites. 
Group 5 was infected by intravenous injection of a 
sporozoite gland suspension.
DOSE 0. AOillNE ADD REACTION 00 oPGiiQZOJiE INPECIION.
Total 












O.lg. daily 21 to 35 days 
for 49 to 69 after start- 
days. ing dosing.
O.lg. daily hirst day 






Loading dose fourth day 
of l.Og. in of 
3 days then dosing.
0.lg. daily 
till day 25.
Loading dose fourth day 
of l.Og. in of 
3 days and dosing. 
O.lg. daily 
for 4 days.
0 2 5 
5 0 0
Group IIA was infected with Italian K.l, malaria.
. , The others were infected with Roumanian M.T. malaria. 
Group IA was infected on 4 occasions, the others on 
one occasion.
Table 3-
EilPLIOATS HSilMlIOS: Of BLOOD MEEAOaJHE. 
(Single Extract ion Method of Brodie and IFdenfriend).




1 2  5
Mean
1 71 7'"7 66 69
z 70 OO 73 69
3 57 80 57 . 71
4 75 71 79 755 80 ou 93 84
6 S3 80 QQOw
7 87 91 87 88
8 - 84 100 84 89
9 84 107 84 92
10 131 138 123 130
11 137 133 137 135
'12 280 291 286 285
Table 4.













A 6 1 77 5 150, 230, 254, 
225 and 337
B 3 2 53 
60
1 113







D 3 1 ' 20 2 220, 260
E 2 2 26 
70 o
P* 5 0 -5 . 220,360,300,316,286 (7 days) 
- 480,448,240,520 (l4days) 
248,680 - 420,408 (20days)
* Group -P had no malarias but the blood levels at 
7 days, 14 days, and 20 days after infection are 
- shown for comparison v/ith the others.
Table 5.












1 .1 .15 5 100
2 1 52 2 228 x
3 - - 2 928
4 3 150 1 288
5 5 224̂ 2 760
*' No. of Day( s) before or after fever















4 12 24 48
(ug. per litre) 
initial dose.
72 96 120
1 1.8 1 220 205 100 200 300 266 395
2 190 160 102 235 235 200 295
5 280 185 117 160 250 225 2804 ISO 125 37 155 185 175 185
5 220 135 67 160 200 — 200
6 - 170 67 145 200 210 185
7 2p5 285 135 240 235 330 395
8 160 120 65 140 200 310 180
Group Mean:- 213 173 86 179 225 245 264
2 3.4 9 52 115 185 190 225 265 450
10 115 135 355 450 725 750 1115
11 160 390 530 525 760 715 1085
12 124 185 280 275 385 665 850
13 68 325 400 570 570 850 700
14 76 270 535 490 705 680 1000
15 . 144 275 410 410 . 550 830 915
Group Mean: - 105 24 9 38 5 415 560 679 873
Hours after initial dose.
8 16 29 53 77 101 125
* 3 3.2 16 132 410 340 590 544 315 665
17 144 360 425 670 690 580 965
18 150 490 455 750 660 700 1030
19 94 295 265 490 525 562 835
20 164 540 540 880 640 800 915
21 144 255 -450 645 500 600 915
22 136 300 300 410 690 600 665
23 88 255 330 510 585 — 830
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BLOOD MSPACjRINE ADTER 0HA1 AD MINI3TRATI0N 01' TABLETS. 







2-g- hrs. 5-J- hrs. 10-J- hrs. 24 hrs.
16 • 33 33 76 73 46 33
17 26 83 275 66 • 33 46
18 73 93 180 46 46 86
19 43 80 73 73 53 5320 130 126 207 80 60 ■—
Mean 61 83 162 67 47 54
Table 11.
BLOOD. MEPACRINE ABTER ORAL AD MIN ISTHATION OB 
MEPACRINE IN SOLUTION.






■f- hr. 2-J- hps. 5-J- hrs.
21 150 208 193 140
22 150 350 153 187
23 183 217 153 233
24 175 183 127 147
25 167 183 253 173
26 175 217 133 187
Mean 166 226 168 178
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Table 12.
BLOOD MEPACRINE AFTER RECTAL INJECTION. 





•|- hr. 2jj hrs. 5g- hrs. 10^ hrs. 24 hrs.
27 240 500 133 120 — 50
28 283 1200 . 86 95 - 55
29 530 365 116 95 100 45
30 335 465 120 140 140 40
Mean 347 632 113 112 120 47
Table 13.
BL001 MEPACRINE APTER INTRAVENOUS INJECTION.
Dose 0.2g. Mepacrine Hydrochloride.
Volunteer Blood Mepacrine (ug./litre) ,
No.
3 Nr -f hr . 2-J- hrs. 6 hrs. 12 hrs . 24 hrs.
31 290 140' 15*0 127 67 / 87
32 340 200 138 120 87 107
33 335 165 - 107 87 107
34 400 190 215 ' 127 67 107r-rr*35 450 330 465 107 140 . 73
Mean 341 173 125 ' 120 771 — t * ■
102
* Part of the dose given subcutaneously. Results 
excluded in calculating the mean blood•mepacrine.
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Table 14.
BLOOD MEPACBIHE AETEH IDTHAMJ3 OULAR INJECTION. 




Blood Mepacrine (ug 
| hr. 2-J- hrs. 6 hrs.
./litre) 
12 hrs. 24 hrs.
36 650 365 185 133 93 11337 385 365 165 107 87 10738 735 350 165 133 120 80
- 39 385 200 . 235 127 93 8740 665 235 150 120 ' 100 73
Mean 564 303 180 124 98 92
Table 15.
BLOOD MEPACBIHE ABTEB SUBCUTANEOUS INJECTION. 




Blood Mepacrine (ug./litre/ 
-f- hr. 2^ hrs. 5-J- hrs. 10-J- hrs. 24 hrs.
41 812 480- ' 153 93 91 53
42 692 286 206 140 133 55
43 195 746 140 93 91 56
44 746 233 106 106 108 53
45 640 313 - 385 153 91 83
Mean 617 412.. 198 117 102 60
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•Table 16.
BLOOD E&PACBINE ABTBR REPEATED BUBCUTANEQUS INJECTIONS,
Volunteer Bipod Mepacrine after the Initial Infection* 
Bo. (ug. per litre)
•Jhr. 2hrs. 2-J-hrs. 5hrs. 5-J-hrs. 9hrs. 24hrs.
1 600 435 1030 265 800 325 145
2 . 800- 430 830 185 - 265 115
3 665 465 1000 180 485 215 85
4 — 430 030 200 535 260 125
Mean. 688 440 947 207 606 266 117
Subcutaneous injections:- 0.2g. at zero hour.
O.lg. at 2 hours and 
at 51 hours.
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Table 17.#    ■ "* ' 1 V





Blood Mepacrine after the Eirst 
(ug. per litre)
f li 3 6 12 24






1 930 565 400 315 165 5440 960 475 416
2 1300 465 305 135 85 345 440 - 292
. 3 1130 300 200 135 90 415 440 383 267
4 665 635- 245 150 165 985 560 666 332
5 800 435 245 185 125 2080 445 333 367 ,
6 330 500 270 150 115 2720 320 300 267
7 365 335 255 150 100 825 665 383 332
8 535 900 335 315 135. 1570 495 336 332
Group 






hy intramuscular injection and
by mouth at zero hour.
by mouth at 6, 14, and 24 hours.
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.58 408 320 260 2-40 380 148 252 200 50 20
59 548 892 — 860 328 — - 84 . ~
60. 300 516 240 420 400 100 140 140 88
61 900 £12 200 — 218 208 272 420 «
62 388 300' 258 288 240 90 130 160 64 go
63 512 440 -430 — 780 200 420 264 58 SO
U 4
548 236 310 403 — 160 200 440 04 10
I Group 




j Volunteers I'©. D4S .609 61, a m ■6-4 vmje© inf§at #4 witli
sporesoI ■$es Oi m  * ivalsrls. ) &i-% £ii&y 4«
Nos SO end 54 lal no rsaeiicM. t© l&jCeotiOil* $f©fl' IP aai 





URINE MEPACRINE AP1BR PROLONGED ADMINISTRATION.




, Q.lg.; day 2, 0 










Urinary Mepacrine (Night urinef
Day Day Day Day Day Day 










58 7.0 22.2 4.8. 7.7 11.2 1.2 3.4 3.9 0.07 0
59 10.0 7.5 - 3.3 8.0 ,1.5 - - 0.10 -
60 2.8 6.1 4.5 2.0 7.3 2.5 1.5 0.8 0.13 ~
61 7.2 9.0 2.0 - 3.8 2.4 0 - - - .
62 4.4 1.6 0.8 4.8 4.6 0.3 0 0.4 0.03 0
63 ia.2 21.0 16.1 - 16.0 7.3 1.1 • 0.2 0.20 0
64 7.4 12.2 7.0 12.2 4.6 4.7 3.3 2.0 0.13 0
Group
Mean 8.1 11.4 5.8 6.0 7.9 2.8 1.6 1.3 0.11 0j
Volunteers No. 59, 60, 61, and 64 were infected with 
sporosoites of 19.1. .malaria (Italian strain) on day 4. 
Nos 60 and 64 had no reaction to infection. Nos 59 
and 61 had fever without parasitaemia, starting on days 
20 and 14 respectively.
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Table. 20.
B100D MEPACRINE • APTER PROLONGED ADMINISTRATION.
Dosage Regime No.(5':- Day 1, O.lg.; day 2, 0.2g.; 
day 3, 0.3g.; day 4, 0.4g.; 
day 5, 0.5g.; and tb.en 0.5g. 










3 40 44 30 16 64 56 41
6 188 168 260 188 132 168 184
13+ 120 168 160 56 64 80 108
20+ 132 120 160 100 80 100 115
27+ - 64 — 80 48 56 62
34+ 160 100 116 132 116 80 117
41+ 120 80 160 116 116 64 109
48+ 132 80 - 116 80 100 101
55+ 168 - 132 - - - 100
69+ 168 64 168 80 80 • - 112
76+ - 116 168 80 64 - 107
+ Weekly doses of O.og. given immediately after 
blood and urine samples were collected..
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Table 21.
URINE MEPACRINE AFTER PROLONGED ADMNI3TRATI0N.
Dosage Regime No.6:~ Day 1, 0.lg.; day 2, 0.2g.; ■
day 3, 0.3g.; day 4, 0.4g.; 
day 5, 0.5g.; and then 0.5g. 
at weekly intervals until day 76.
Day
Urinary Mepacrine before and after 
(mgm. per 3 hours). 
Volunteer No:- 
65 66 67 68 69
the Weekly Dose.
70 Group , 
. '___ . Mean.
13+ 0.3 6 0.11 .0.20 0.28 0.37 0.82 0.35
14 0.38 0.49 0.44 ~ - 0.61 0.48
20 + 1.0 0.66 0.42 0.65 0.18 0.73 0.61
21 - - 0.64 - - -
27 + — 0.42 • 0.48 0.35 0.55 0.63 0.49-
' 28 - 0.66 0.94 0.82 0.89 0.85 0.83
34+ 0.24 0.28 0.34 0.21 0.31 0.50 0.3135 1.50 1.24 • 2.11 1.0 • 1.53 1.10 1.^1
41+ 0.34 0.3.3 0.29 _ — 0.28 0.3142 2.70 2.30 2.40 1.45 1.69 1.19 1.95
48+ 0.34 0.15 . ... _ 0.24 0.24
49 2.11 2.0 - 1.53 1.94 1.63 1.84
55^ 0.27 0.26 — 0.25 0.2656 - 2.33 - - — 1.64
69+ 0.63 0.14 0.36 0.19 0.22 - 0,3176 — — • ■ — — —
76+ 0.30 0.66 0.17 — 0.3877 — 1.34 2.56 — — —
Weekly dose of O.bg. given immediately niter "blood and 
urine samples were collected.
fable 22
-iBCOYBRY OP MSEAQRIMB A ll lD  10 PAaeSSS.
50 Egm. mepacrine added to each stool at aero hour, \
Stool Sample Mg. Mepacrine recovered at»**
Slirs • 241irs.. 481irs. 72'toa.
t>. 1 33.8 28.3 *4 • O 7.52 51 • 2 2 . 0 8.0 7,0
1 34. S 23.0 10.1
B 2 38.6 9 9*v. . i U. 6
3 36.2 o o<v ̂3 • U 8.7
1 53.6 22.1 '
G 2 37.6 23.5
3 40.0 24.7
Mean Recovery -
Mgm. 35.7 ‘23.9 9.1 7*2
Per cent. 71.4 1 47.8 18.2 14,4
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Tables 23 - 29.















23-. ?!■ *4>M.ug/L . 160 160 132 160 168 160UM. nig/li 3.9 0.5 2.2 1.2 2.6 2.1
UM.mg/24fcirs 5.7 10.1 3.2. 4.2 5.1 3.8
PM. mg/2‘Bars IB • 0 51.5 42.6 23.0 35.6
24 72 BM. ug/L 80 • 100 120 • 132 100 64
UM.mg/L 2.0 4.7 1.4 0.9 2.2 1.5
UM. mg/2-ilirs 5.8 6.0 2.7 1.9 2.9 3.6
I'M. mg/2 4hrs 10.7 34.3 40.0 18.7 — 33.3
25 ' 73 BM.ug/L 80 132 116 80 116• . UK.mg/L 5. 5 * 4.7 1.9 — — —
UM.mg/24iirs 11.9 7.6 0.5 — — —
BM.mg/243ars 17.3 52.6 38.3 oo. 8 22.2 14.3
; 26 • 74 BM.ug/L .80 64 100 80 100 72
■ UM.mg/L 1.7 2.2 1.1 1.0 1.2 1.3- UM.mg/24hrs 2.2 2.1- 5; 9 1.0 3.7 2.1L BM.mg/24hrs 30.1 30.0 20.0 24.0 15.3
* 31-.,. = Blood Mepacrine.
UM. = Urinary Mepacrine.
Hi. = Jj’aecal Mepacrine.
i
r
Continued on next page.







Dosage Hegime O.lg. meiiacrine daily.
•63
Day of Dosing
64 65 66 67 68
27 75 BM.ug/L 116 80 160 116 116 80UM. rng/L 2 * 4 5 .5 1.4 1.1 2.0 1.3U: '. mg/2 4iirs 4.4 4.6 2.9 3.0 4.7 3.0UM. mg/2'dir s 2.7 55.6 15.1 84.4 20.0 38.5
28 .76 BM.ug/L 80 80 120 80 72UM.rng/L ■ - . - 1.1 1.2 1.8 1.1UM.. mg/24hrs - - 2.9 2.9' 4.9 4.3B M . rug/2 ilir s LO•o 1—1 — 51.6 16.4 # 18.4 . 17.7
29 77 BM.ug/1 100 72 120 sb
UM.mg/L 2.6 3.9 1.9 1.0 2.9 2.4
UM.mg/2-ihrs 4.5 11.0 2.7 1.6 5.0 3.5
■ • BM.mg/24hrs 9.5 19.0 54.5 22.0. 29.0
- 22 -
Table 30.














77 160 - - 7.4
78 116 0.07 0.14 5.8
79 160 0.03 ’ 0.06 6.1
80 168 2.70 4.0 81.6
81 160 3.0 5.0 24.3
82 160 1.90 2.3 23.0
83 ' 132 _ • 1.1 ' 2.2 ■ 9.2
84 - 0.06 0.15 7.0
85 - 0.08 0.17 -
- 23 -
Table 31.




0 600 550 575
1 420 400 410
2 320 320 320
3 260 240 250
4 200 200 200
5 200 200 200
6 160 160 160
7 160 160 160



















0 120 0 10.2
1 120 ■ 1- 9.8
2 120 2 - •
3 100 3 10.2
• 4 ' 100 4 -
5 - '5 9.8
6 80 6 . • 9.5 .
7- - 7 9.5
- 25 -
■/0- ' ' 
Table 33.
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DEGBADAIION OS' MEPACRINE IN, INCUBASED BLOOD 




























Blood Mepacrine ug./litre "
Volunteer 
*C B. I B
1. Volunteer 2. 
C B. IB.
Volunteer 3. 
C B. IB. Volunteer 4. C B. I B.
' 0 _ - 600 600 360 360 - -
1 630 600 530 540 • ' 290 300 100 140
,
2 420 400 410 460 280 260 100 80
■A 3 350 360 -340 400 230 240 ■ 80 60
4 ' 290. 320 310 280 180 180 60 60
.5 160 140 200 200 160 160 40 40
7 - 120 120 180 150 120 100 40 40
* C B. = Circulating Blood.. 
I B. = Incubated Blood.
- 28 -
Table 36>.
BLOOD P1A6UA AND URINARY MDIACEINE8 DURING DOBING.
Dosage Regime ;- 0.6g. mepacrine day 1.
0.3g. w days 2 to 5.1
Volun­ Blood Mepacrine ug./litre
teer Hours after initial dose:-■ No. 4 24 48 , 72 96 120 '
1 220 100 200 300 266 395
2 190 102 255 235 200 295
3 280 117 160 250 225 280
■ / 1 \ ~ i 190 57 '155 185 175 185(—  ! 5 j 220' 67 160 200 - 200'
6 67 145 200 210 185
7 23d 135 240 255 330 395
8 ISO 65 140 200 310 180
- Plasma mepacrine ug. /litre.
1 25 , 27 35 33 40 41
2 26 17 40 43 29 -
3 44 22 36 • 25 40’ ' 58
4 26 17 30 27 53 23
5 38 22 30 40- - 29
6 44 21 40 33 33 23
7 /• /, 15 i—r* r̂r?oo oo 33 44
8 32 22 36 33 30 23
Urinary Mepacrine mg./24Hrs. •
Hours;—
0-24 24t—i8 48-72 72-96 96-•120
1 6.52 ' a; r* V • oO — —
2 4.88 O • zj O 10.05 8.11 5.18
3 3.72 6.56 6.95 8.99 .9.024 2.20 6.23 5.01 5.30 6.44
5 4.07 6.72 10.40 15.55 10. 52
6 2-. 61 5.18 6.88 7.62 6.51
7 6.42 lu • 10.98 11.34 10. 83
8
5.18 O  • 6 .36 6.28 6.54
Table 37.
BLOOD PLAOMA AMD URINARY IlIOEAORINDO AFTER DOSING.
Dosage:-o 3.4.6;. mepacrine in the previous 7 days •
Volun­ Blood Mepacrine ug./litre ,
teer - Days after last dose of meioacrine.
No. 1 2 3 ' 5 6 9 12 14 16 20 27
1 283 262 802 165 159 109 74 57 86 69 34
2 239 216 267 142 130 ' 91 51 40 40 46 28
• 3 240 256 246 97 109 86 51 34 34 63 34
4 262 275 256 171 165 126 45 51 51 74 28
5 228 246 239 105 115 75 34 34 46 69 28rto ooo 273 252 69 97 80 54 28 40 40 28
7 807 234 240 120 142 86 63 57 51 63 34
8 210 177 194 103 126 80 45 45 51 63 34 ■9 233 194 216 80 97 51 34 51 28 46 28
10 0 90/O Of 205 200 115 . 86 65 28 34 40 51 28
Plasma Mepacrine ug. /litre.
1 40 46 74 >. 11 17 44 14 11 23 34 .172 31 40 40 11 11 , 4:3 2 7 6 23 17
3 40 51 28 17 11 40 D 7 6 28 234 23 36 57 12 17 41 11 11 6 28 17
5 17 23 46 22 6 40 11 5 6 23 17
6 23 23 25 22 11 40 13 2 11 23 11
7 — 40 51 17 6 21 15 4 0 23 17
8 17 46 37 11 11 27 14 7 6 28 23
9 31 31 46 12 11 14 13 8 6 28 1710 28 28 28 11 11 27 14 7 6 28 23
Urinary Mep acrine mg*/3 hrs.
1 1.0 . 1.50 0.93 0.79 0.73 0.40 0.31 0.22 0.21 0.16 0.082 0.70 0 .4 a 1.50 1.0 0.70 0.24 0.27 0.19 0.11 0.13 0.09
3 0.76 0.84 0.30 0.48 0.36 0.07 0.13 0.15 0.12 0.10 0.354 1.50 1.02 1.82 0.71 1.0 0.22 0.40 0.28 0 • 2d 0.24 0.105 1.20 1.20 0.82 0.85 0.56 0.13 0 .14 0.19 0.31 0.12 0.096 0.91 0.44 0.18 0.50 0.15 n r3 o U • u 0.17 0.16 0.46 0.07 0.27








Daily Urinary Output, ml.
5 Day-2 Day-1 Day of
lest.
1 800 600 60 240
2 1040 500 220 440
3 840 600 360 720
• 4 900 870 540 900
5 940 720 100 • ' 760




7 — — — . 2100
8 - - - 2360 -
9 — — - 1800 - ,
10 — - — 1700
11 - - - 2080




BLOOD MEPACRINE ADD'BLUID INTAKE.
Volunteer




it hr. t  hr 2-J- hrs 5 hrs 10 hrs 14jjr hrs 23i hrs
1 - 133 217 167 433 233 333 250
2 150 217 133 187 150 283 317
3 # 133 192 180 2o3 258 517 767
4 141 192 260 173 125 300 433
5 133 242 120 193 233 583 633
6 150 203 127 193 167 333 383
Group Mean 140 211 164 235 194 392 463
• Liberal Eluid Intake Group
♦
7 150 208 193 140 167 450 6338 150 350 153 187 167 333 4339 183 217 153 2 Oil) 158 267 46710 175 . 183 127 147 158 267 46711 167 183 253 173 ' 83 * 200 317- 12 175 217 133 187 158 367 600
Group Mean 166 226 169 178 148 314 486
32 -
Table 40.
U R I M R Y  MEPACRINE AND ELUID INTAKE.
Volunteer
•Restricted Eluid Intake Group 
Urine
Volume 




1 240 3 .6 0.9.
2 440 5.3 2.3
3 720 6.6 4.7
4 900 10.3 9.3
5 760 2.6 1.9
6 900 11.0 9.9
Group
Mean '660 6.6 4.8
Liberal Eluid Intake Group
7 '2100 8.6 18.1
8 2360- 9.6 22 .'6
9 1800 8.6 15.5
10 . 1700 6.6 11.2
11 2080 6.0 12.5
12 2400 7.1 17.1
Group
Mean - 2073 7.7 16.1
BLOOD 1V1BPA GRIND AND SEVERE TONIC EBRD CIO.
Doss,ge Regime:- 0 . og. mepacrine daily for b days
Blood Mepacrine ug./litre
Day * Severe foxic Effects No Symptoms
I. G. G. K. Cn. P.
5 670 430 692 288 220 206
• 6 1116 1076 CO *%2 768 558 440
7 700 ~ - , - 1 - ' -
8 - 487 228- 281 618 187'
9 83-8 - - -- . - -
10 - - - - -
11 310 214 470 230 247 "164
13 224 213 197 - 213 262 180
Severe toxic effects from days 6 to 10. 





URINARY MRPACRINE AM) SEVERE TOXIC EEEECTS,
Do sage Regime s-- 0 .5g. mepacrine daily for 3 days.
. ***Urinary Mepaorine mg./24 hours
Day 'Severe Toxic Effects No Symptoms
I. Gr. C. K. Cn. E.
+
* 1 4.3 2.1 3.1 6.0 4.9 0.5
2 3.7 4.2 2.1 3.8 •'•i • 3 10.3
3 8.7 5.0 9.5 12.2 4.0 9.3
4 16.2 12.5 18.3 . 14.1 17.1 16.6
5 20.9 21.5 29.0. 20.1 17.8 21.3
6 16.9 14.6 22.7 . 25.2 4.3 -
' 7 16.3* 12.3 20.6 8.3 13.0 -
8 15.2 2.7 14.8 5.7 5.3 9.8
9 . ' 9.2 5.3 14.0 12.9 6.8 3.8
10 10.7 6.0 10.9 7.7 2.5 7.3
11 7.5 3.9 .7.0 10.5 4.3 5.7
12 5.2 ■ 4.7 
. ... . . .... 1

























































































G R A P H  2.









o 4 82 20 226 14 1816lO 12
D $ y5 a^t’or Sp orozo ite  injection. 
Volunteers A, B, C, and I) were infected on one occasion with 
sporozoites of M.T. malaria.
A and B received O.lg. mepacrine daily for 20 days and began 
dosing on the day of infection. A developed malaria; B 
had a mild fever of a few hours duration (peak temperature 
100°!.) but parasites were not found in the blood.
G and D received l.Og. mepacrine in 3 days. G was given 
O.lg. two days before infection, 0.3g. one day before 
infection and 0 .6g. on the day of infection. D received 
O.lg. 3 days after infection, 0.3'g. four days after infection 
end 0.6g. five days after infection.
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D 0 5 E  A I> iD  G K p U P  t A E A I ^  
_______BLOOD M E P A C P J I j E .
R egim e 1- T ota l d o s e  l ' 8 g. «— •



























D O S E  A!\[D G R p U P  M E A f i [  
UF^II^AF^Y A \ E P A C R J K £ .
regime * 1 ‘ Total dose 1 * 8 g. 
KySgitne-2' Total dose 3 ‘4g. 









' G ^ A P H  6 .







g ,  M gp
5 J^ectal injection 
s Subcutaneous injection 
3 Intramuscular injection 
* Intravenous irijection
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BLOOD A1(D U M E P A C H l ^ A P  DUÎ VTI0D( OF D05IB[G.
200
100
D05AGE REGIME 6 .  o* l g  Kzp&cnm  daily .
80 9080







G i \ A P ) 1  1 0
BLOOD Al'CD UR|J\[AKy AVEPACKJ^E Af(D DUI\A.TIOt{OF D05IH&
2X>
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DO 5AGE REGIME 7 :
Day i o • 1 g. Alepacrine.
Day 2 o -3g.
Day 3 0'6g.
Day 4  to 25 o-lg. daily.
Group Moan Blood X opacrine. 
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R/VTE OF DEGF^ADATIOK OF






1 £ 3 4 5 6 r



























f \ A T £  OF D E G R A D A T I O N  OF/HEPACKIt^E  
IK BL O O D  OF THREE VOLUNTEERS A ,B * n d C  
W ITH  D IFFER EN T IK IT IA L C O N C ER TR A TIO NS.
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M E P A C R I N E  P A R T I T I O N  A N D
C O N C E N T R A T IO N  OFM EPACRINE 5 0 L U T I0 N
6h
loo 2oo 3oo 4oo 5oo 6oo 7oo 8oo 9oo looo
C O N C E N T R A T IO N  O F  M E P A C R I N E  
5 0 L U T I 0 K  ( tog. p e r  litre)
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GĴ APJI 17.
MEPACRJ1N[£ PARTITION AI^D pH  T E M P E R A T U R E  
AI\[D ELEC TR O LY TE C O R C E R T R A .T IO I1
*~~X— - X -





























































CKpUP M E A H  BLOOD Ul^lKE A N [P  P L A S i A A
iA E P A C ^ lK L g  PUFJH.CI DQ51HG.
in











































_  • ••
io £0 30 40 5o 60
Ptasmfc, i^epScCrino ai g / litr e
G R ^ P J I  2 0
BLOOD MEPACpII^E AI^D U^INA^X 







O 5o loo 1 6 0  2oo 26o 3oo 35o 4oo 
£>lood .Alep&crine ^ug/Utre.
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G f \ A P H  2 1 .
G f p J P  M E  A H  B L O O D  U R J H A ^ Y  A l^ D  P L A S M A .  
M E P A C R J H E S  A F T E R ,. D 0 8 1  h o  .
8&  25o
S 52oo
P  . *
O  <j 150
o  g
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\ \ Urinary MepoucxtnG.
Plasma, MepooLrine
2 4 6 8 IO 12 14 16 18 2o 22 24 26
D<xy5 a.j’trer Ia s It dooe oj Mepcxccinc.
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G R fO P H  2 £
PLASMA M EPAC^JH E A ^D  
UPJf{Af\Y MEPAC^IHE AFTE^ DOSING.
"Io 2 b 3o 4o 5o 60
Pldwstn&c M.cpas,crine ^ g ./ litreGRAPH 23
BLOOD M EPACRJHE AT^D URJHARJf 
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